DonId,Cause,Effect,Causality_Type,Raw_Text,Cause_category,Effect_category
2024-DON540,high CFR (24-88%),MVD is an epidemic-prone disease,T1,"Marburg virus disease (MVD) is caused by the same family of viruses (Filoviridae) that causes Ebola virus disease. MVD is an epidemic-prone disease associated with (C1) high CFR (24-88%) (C1). In the early course of the disease, (C2) MVD is challenging to distinguish from other infectious diseases such as malaria, typhoid fever, shigellosis, meningitis and other viral haemorrhagic fevers (C2).",mortality rate,disease risk
2024-DON540,MVD is challenging to distinguish from other infectious diseases,[No relevant effect related to disease transmission or emergence],[Not applicable],"Marburg virus disease (MVD) is caused by the same family of viruses (Filoviridae) that causes Ebola virus disease. MVD is an epidemic-prone disease associated with (C1) high CFR (24-88%) (C1). In the early course of the disease, (C2) MVD is challenging to distinguish from other infectious diseases such as malaria, typhoid fever, shigellosis, meningitis and other viral haemorrhagic fevers (C2).",disease differentiation,No impact
2024-DON540,Healthcare-associated infections (also known as nosocomial infections) of this disease,further spread,T1,"Epidemiologic features can help differentiate between viral hemorrhagic fevers (including history of exposure to bats, caves, or mining) and laboratory testing is important to confirm the diagnosis. With 62 confirmed cases reported, this is the third largest MVD outbreak reported, with the majority of confirmed cases reported among healthcare workers. (C1) Healthcare-associated infections (also known as nosocomial infections) of this disease (C1) can lead to (E1) further spread (E1) if not controlled early.",hospital infections,disease spread
2024-DON540,,,No causality,"The importance of screening all persons entering health facilities as well as inpatient surveillance for prompt identification, isolation, and notification cannot be overemphasized. This is in addition to the importance of contact identification and monitoring of all probable and confirmed cases. The source of the outbreak, the likely date of onset of the first case and additional epidemiological information on cases are still pending further outbreak investigation. On 30 September WHO assessed the risk of this outbreak as very high at the national level, high at the regional level, and low at the global level.",No context,No context
2024-DON540,contact with the body fluids of a sick patient presenting with symptoms,MVD transmission,T1,"However, based on the evolution of the outbreak and ongoing investigations, this risk assessment may be revised. MVD is not easily transmissible (i.e. in most instances it requires (C1) contact with the body fluids of a sick patient presenting with symptoms (C1) or with (C1) surfaces contaminated with these fluids (C1)).",disease transmission,disease transmission
2024-DON540,surfaces contaminated with these fluids,MVD transmission,T1,"However, based on the evolution of the outbreak and ongoing investigations, this risk assessment may be revised. MVD is not easily transmissible (i.e. in most instances it requires (C1) contact with the body fluids of a sick patient presenting with symptoms (C1) or with (C1) surfaces contaminated with these fluids (C1)).",environmental transmission,disease transmission
2024-DON540,public health measures,"active surveillance in facilities and communities, testing suspected cases, isolation and treatment of cases, and contact tracing",T2,"In addition, there are ongoing (C1) public health measures (C1) in place, including (E1) active surveillance in facilities and communities (E1), (E1) testing suspected cases (E1), (E1) isolation and treatment of cases (E1), and (E1) contact tracing (E1).",disease prevention,disease control
2024-DON538,mosquito bites,transmission of WNV,T1,"Although no cases of WNV have been documented in birds or horses in the country, it is possible that the virus is circulating in these populations undetected. Despite this, the overall impact on public health remains limited at this stage, as there is currently only one recorded human case and appropriate public health response measures have been implemented, as described above. The risk of international dissemination of WNV from Barbados is low. The virus is primarily transmitted through (C1) mosquito bites (C1), with (C2) birds as the natural hosts (C2). There is no evidence to suggest that WNV spreads easily between humans or from horses to mosquitoes.",insect transmission,disease transmission
2024-DON538,birds as the natural hosts,transmission of WNV,T1,"Although no cases of WNV have been documented in birds or horses in the country, it is possible that the virus is circulating in these populations undetected. Despite this, the overall impact on public health remains limited at this stage, as there is currently only one recorded human case and appropriate public health response measures have been implemented, as described above. The risk of international dissemination of WNV from Barbados is low. The virus is primarily transmitted through (C1) mosquito bites (C1), with (C2) birds as the natural hosts (C2). There is no evidence to suggest that WNV spreads easily between humans or from horses to mosquitoes.",animal reservoir,disease transmission
2024-DON538,,,No causality,The input text does not contain any relevant causality related to the emergence or transmission of pests and pathogens.,No context,No context
2024-DON536,locally within KSA,MERS-CoV infection,T1,"Since the first report of MERS-CoV in the Kingdom of Saudi Arabia (KSA) in 2012 until now, human infections have been reported in 27 countries, spanning all six WHO regions. The majority of MERS-CoV cases (2205; 84%), have been reported in KSA, including this newly reported case. The notification of this case does not change the overall risk assessment. The new case reported is believed to have acquired (E1) MERS-CoV infection (E1) locally within KSA.",regional spread,disease transmission
2024-DON536,visited Pakistan,international transmission,T3,"However, the potential for (E1) international transmission (E1) is increased due to the fact that the individual visited (C1) Pakistan (C1), while a high-risk contact traveled to (C1) South Asia (C1) within the 14-day follow-up period. Both individuals had arranged their travels prior to the occurrence of the event and before the test results of the case were obtained and disseminated. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where (E2) MERS-CoV is circulating in dromedaries (E2). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, consumption of raw camel milk), or in a (C3) health-care setting (C3).",travel history,global spread
2024-DON536,traveled to South Asia,international transmission,T3,"However, the potential for (E1) international transmission (E1) is increased due to the fact that the individual visited (C1) Pakistan (C1), while a high-risk contact traveled to (C1) South Asia (C1) within the 14-day follow-up period. Both individuals had arranged their travels prior to the occurrence of the event and before the test results of the case were obtained and disseminated. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where (E2) MERS-CoV is circulating in dromedaries (E2). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, consumption of raw camel milk), or in a (C3) health-care setting (C3).",travel exposure,global spread
2024-DON536,contact with dromedaries or their products,MERS-CoV is circulating in dromedaries,T1,"However, the potential for (E1) international transmission (E1) is increased due to the fact that the individual visited (C1) Pakistan (C1), while a high-risk contact traveled to (C1) South Asia (C1) within the 14-day follow-up period. Both individuals had arranged their travels prior to the occurrence of the event and before the test results of the case were obtained and disseminated. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where (E2) MERS-CoV is circulating in dromedaries (E2). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, consumption of raw camel milk), or in a (C3) health-care setting (C3).",animal contact,animal reservoir
2024-DON536,health-care setting,MERS-CoV is circulating in dromedaries,T1,"However, the potential for (E1) international transmission (E1) is increased due to the fact that the individual visited (C1) Pakistan (C1), while a high-risk contact traveled to (C1) South Asia (C1) within the 14-day follow-up period. Both individuals had arranged their travels prior to the occurrence of the event and before the test results of the case were obtained and disseminated. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where (E2) MERS-CoV is circulating in dromedaries (E2). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, consumption of raw camel milk), or in a (C3) health-care setting (C3).",medical environment,animal reservoir
2024-DON536,delays in identifying the infection,Human-to-human transmission of MERS-CoV,T3,"Human-to-human transmission of MERS-CoV may occur if there are (C1) delays in identifying the infection (C1), particularly in countries that are not well-acquainted with the disease, as well as (C1) slow triage of suspected cases (C1) and (C1) delays in the implementation of standard infection prevention and control measures (C1). WHO continues to monitor the epidemiological situation and conducts risk assessments based on the latest available information.",diagnostic delays,disease transmission
2024-DON536,slow triage of suspected cases,Human-to-human transmission of MERS-CoV,T3,"Human-to-human transmission of MERS-CoV may occur if there are (C1) delays in identifying the infection (C1), particularly in countries that are not well-acquainted with the disease, as well as (C1) slow triage of suspected cases (C1) and (C1) delays in the implementation of standard infection prevention and control measures (C1). WHO continues to monitor the epidemiological situation and conducts risk assessments based on the latest available information.",delayed response,disease transmission
2024-DON536,delays in the implementation of standard infection prevention and control measures,Human-to-human transmission of MERS-CoV,T3,"Human-to-human transmission of MERS-CoV may occur if there are (C1) delays in identifying the infection (C1), particularly in countries that are not well-acquainted with the disease, as well as (C1) slow triage of suspected cases (C1) and (C1) delays in the implementation of standard infection prevention and control measures (C1). WHO continues to monitor the epidemiological situation and conducts risk assessments based on the latest available information.",control lapses,disease transmission
2024-DON537,high CFR (24-88%),epidemic-prone nature of MVD,T1,"Marburg virus disease (MVD) is caused by the same family of viruses (Filoviridae) that causes Ebola disease. MVD is an epidemic-prone disease associated with (C1) high CFR (24-88%) (C1). In the early course of the disease, (C2) clinical diagnosis of MVD is challenging to distinguish from other infectious diseases such as malaria, typhoid fever, shigellosis, meningitis, and other viral haemorrhagic fevers (C2).",mortality rate,disease outbreak
2024-DON537,clinical diagnosis of MVD is challenging,difficulty in distinguishing MVD from other infectious diseases,T1,"Marburg virus disease (MVD) is caused by the same family of viruses (Filoviridae) that causes Ebola disease. MVD is an epidemic-prone disease associated with (C1) high CFR (24-88%) (C1). In the early course of the disease, (C2) clinical diagnosis of MVD is challenging to distinguish from other infectious diseases such as malaria, typhoid fever, shigellosis, meningitis, and other viral haemorrhagic fevers (C2).",diagnosis challenges,diagnostic challenges
2024-DON537,Healthcare-associated infections,further spread,T1,"Epidemiologic features can help differentiate between viral hemorrhagic fevers (including history of exposure to bats, caves, or mining) and laboratory testing is important to confirm the diagnosis. The notification of 26 confirmed cases, of which over 70% are healthcare workers from two different health facilities in the country is of great concern. (C1) Healthcare-associated infections (C1) of this disease can lead to (E1) further spread (E1) if not controlled early. The importance of screening all persons entering health facilities as well as inpatient surveillance for prompt identification, isolation, and notification cannot be overemphasized.",hospital hygiene,disease spread
2024-DON537,"cases have been reported in districts located at the borders with the Democratic Republic of the Congo, the United Republic of Tanzania, and Uganda",risk of this outbreak spreading to neighbouring countries,T1,"This is in addition to the importance of contact identification and monitoring of all probable and confirmed cases. The source of the outbreak, geographical extent, the likely date of onset, and additional epidemiological information on cases are still pending further outbreak investigation. There is a (E1) risk of this outbreak spreading to neighbouring countries (E1) since (C1) cases have been reported in districts located at the borders with the Democratic Republic of the Congo, the United Republic of Tanzania, and Uganda (C1). Further (E2) risk of international spread (E2) is also high as (C2) confirmed cases have been reported in the capital city with an international airport and road networks to several cities in East Africa (C2).",border transmission,regional spread
2024-DON537,confirmed cases have been reported in the capital city with an international airport and road networks to several cities in East Africa,risk of international spread,T1,"This is in addition to the importance of contact identification and monitoring of all probable and confirmed cases. The source of the outbreak, geographical extent, the likely date of onset, and additional epidemiological information on cases are still pending further outbreak investigation. There is a (E1) risk of this outbreak spreading to neighbouring countries (E1) since (C1) cases have been reported in districts located at the borders with the Democratic Republic of the Congo, the United Republic of Tanzania, and Uganda (C1). Further (E2) risk of international spread (E2) is also high as (C2) confirmed cases have been reported in the capital city with an international airport and road networks to several cities in East Africa (C2).",urban spread,global transmission
2024-DON537,"Optimized supportive care for patients, which includes careful monitoring, intravenous fluid, and early treatment of complications",patient survival,T1,"A contact is known to have travelled internationally, to Belgium, and appropriate response measures have been implemented. Optimized supportive care for patients, which includes careful monitoring, intravenous fluid, and early treatment of complications, can improve (E1) patient survival (E1). There are promising vaccines and therapeutic candidates for MVD, but these must be proven in clinical trials.",patient care,patient outcomes
2024-DON537,,,No causality,"&nbsp;WHO has provided guidance to the Ministry of Health on how to manage cases. WHO assesses the risk of this outbreak as very high at the national level, high at the regional level, and low at the global level.&nbsp; Investigations are ongoing to determine the full extent of the outbreak and this risk assessment will be updated as more information is received.&nbsp;&nbsp;.",No context,No context
2024-DON534,contact with infected poultry or environments that have been contaminated,mild clinical symptoms,T1,This is the first human case of infection with a zoonotic influenza virus notified by Ghana. Laboratory testing confirmed the virus as an influenza A(H9N2) virus. The majority of human infections with A(H9N2) viruses occur due to (C1) contact with infected poultry or environments that have been contaminated (C1) and typically result in (E1) mild clinical symptoms (E1). Further human cases in persons with exposure to the virus in infected animals or through contaminated environments can be expected since the virus continues to be detected in poultry populations.,animal contact,symptom severity
2024-DON534,capacity for sustained transmission among humans,likelihood of sustained human-to-human spread,T1,"To date, there has been no reported sustained human-to-human transmission of A(H9N2) viruses. The existing epidemiological and virological evidence suggests that this virus has not acquired the (C1) capacity for sustained transmission among humans (C1). Thus, the (E1) likelihood of sustained human-to-human spread (E1) is low. Should infected individuals from affected areas travel internationally, their (C2) infection (C2) may be detected in another country during travel or after arrival.",disease spread,disease spread
2024-DON534,infection,detection in another country,T1,"To date, there has been no reported sustained human-to-human transmission of A(H9N2) viruses. The existing epidemiological and virological evidence suggests that this virus has not acquired the (C1) capacity for sustained transmission among humans (C1). Thus, the (E1) likelihood of sustained human-to-human spread (E1) is low. Should infected individuals from affected areas travel internationally, their (C2) infection (C2) may be detected in another country during travel or after arrival.",disease transmission,global surveillance
2024-DON534,,,No causality,"However, if this occurs, further (E1) community-level spread (E1) is considered unlikely.",No context,No context
2024-DON532,exposure to swine influenza viruses through direct contact with infected swine or indirectly through contaminated environments,human cases with influenza A(H1N1)v virus infection,T3,"Human infections with swine-origin influenza viruses have been reported in recent years from many countries. Most human cases with influenza A(H1N1)v virus infection result from (C1) exposure to swine influenza viruses through direct contact with infected swine (C1) or (C1) indirectly through contaminated environments (C1). However, a few cases have been reported without an apparent source of exposure to swine in the weeks prior to illness onset.",animal exposure,disease transmission
2024-DON532,,,No causality,"Because these viruses continue to be detected in swine populations worldwide, further human cases following direct or indirect contact with infected swine can be expected. Limited, non-sustained human-to-human transmission of variant influenza viruses has been described, although ongoing community transmission has never been identified. Current evidence suggests that these viruses have not acquired the capacity for sustained transmission among humans.",No context,No context
2024-DON532,,,No causality,"According to the information available thus far, no further human cases of infection with A(H1N1)v viruses associated with this case have been detected. Based on the available information, WHO assesses the current (E1) risk to the general population posed by this virus to be low (E1). Further virus characterization is ongoing. The (E1) risk assessment (E1) will be reviewed should further epidemiological or virological information become available.",No content,No context
2024-DON533,"close contact with A(H5N1)-infected live or dead birds or mammals, or contaminated environments",A(H5N1) viruses have not acquired the capacity for sustained transmission among humans,T1,"From 2003 to 20 August 2024, a total of 903 human cases of infection of influenza A(H5N1) have been reported globally to WHO from 24 countries, including this case. Almost all cases of human infection with avian influenza A(H5N1) have been linked to (C1) close contact with A(H5N1)-infected live or dead birds or mammals, or contaminated environments (C1). Available epidemiological and virological evidence suggests that (E1) A(H5N1) viruses have not acquired the capacity for sustained transmission among humans (E1).",animal exposure,disease transmission
2024-DON533,"virus continues to circulate in poultry, particularly in rural areas in Cambodia",sporadic human cases can be expected,T1,"Therefore, the likelihood of sustained human-to-human spread is low at present. Since the (C1) virus continues to circulate in poultry, particularly in rural areas in Cambodia (C1), further (E1) sporadic human cases can be expected (E1). Currently, based on available information, WHO assesses the overall public health risk posed by this virus to be low.",animal transmission,disease occurrence
2024-DON533,Vaccines against seasonal influenza viruses,infections with influenza A(H5N1) viruses,T1,"The risk assessment will be reviewed as needed if additional information becomes available. Close analysis of the epidemiological situation, further characterization of the most recent influenza A(H5N1) viruses in both human and poultry populations, and serological investigations are critical to assess associated risks to public health and promptly adjust risk management measures. Vaccines against seasonal influenza viruses will not protect humans against (E1) infections with influenza A(H5N1) viruses (E1). Candidate vaccines to prevent influenza A(H5) infection in humans have been developed for pandemic preparedness in some countries. WHO continues to update the list of zoonotic influenza candidate vaccine viruses (CVV), which are selected twice a year at the WHO consultation on influenza virus vaccine composition.",disease prevention,viral infections
2024-DON533,,,No causality,"The list of such CVVs is available on the WHO website, at the reference below. In addition, the genetic and antigenic characterization of contemporary zoonotic influenza viruses is published here.",No context,No context
2024-DON531,individual factors such as potential exposures and immunity status,community transmission without any travel link,T1,"Regardless of geographic area, epidemiological context, gender identity or sexual behaviour, individual-level risk is largely dependent on (C1) individual factors such as potential exposures and immunity status (C1). This case represents the first ever report of mpox due to clade I MPXV outside of the African region. Further sporadic cases may be expected, whether among travelers from endemic areas / countries or appearing through (E1) community transmission without any travel link (E1). Further spread of the disease within Sweden from this first case was assessed by Swedish authorities as very low due to the (C2) appropriate public health measures that have been put in place (C2). However, the travel history of this case is still under investigation, and the case was experiencing symptoms (and was therefore likely to be infectious) during international travel.",individual health,local spread
2024-DON531,appropriate public health measures that have been put in place,very low further spread of the disease within Sweden,T1,"Regardless of geographic area, epidemiological context, gender identity or sexual behaviour, individual-level risk is largely dependent on (C1) individual factors such as potential exposures and immunity status (C1). This case represents the first ever report of mpox due to clade I MPXV outside of the African region. Further sporadic cases may be expected, whether among travelers from endemic areas / countries or appearing through (E1) community transmission without any travel link (E1). Further spread of the disease within Sweden from this first case was assessed by Swedish authorities as very low due to the (C2) appropriate public health measures that have been put in place (C2). However, the travel history of this case is still under investigation, and the case was experiencing symptoms (and was therefore likely to be infectious) during international travel.",health management,disease spread
2024-DON531,,,No causality,"To date, this appears to be an isolated case for which one close contact is under monitoring.",No context,No context
2024-DON530,potential expansion of the virus's transmission area,overall public health risk posed by this virus to be high at the regional level,T3,"In the Region of the Americas, outbreaks of Oropouche virus disease have occurred mainly in the Amazon region during the last ten years. With geographical limitations, OROV causing persistent endemicity and periodic outbreaks are reported in both rural and urban communities in Brazil, the Plurinational State of Bolivia, Cuba, Colombia, Ecuador, French Guiana, Panama, Peru, and Trinidad and Tobago. The ongoing outbreak highlights the need to strengthen epidemiological and entomological surveillance and to reinforce preventive measures in the population. This is crucial due to the (C1) potential expansion of the virus's transmission area (C1) and the (C1) growing understanding of the disease spectrum (C1), including possible new transmission routes, and possible new vectors that could affect both the general population and vulnerable groups, such as pregnant women, their fetuses, and newborns. Based on available information, WHO assesses the (E1) overall public health risk posed by this virus to be high at the regional level (E1) and low at the global level.",disease spread,health risk
2024-DON530,growing understanding of the disease spectrum,overall public health risk posed by this virus to be high at the regional level,T3,"In the Region of the Americas, outbreaks of Oropouche virus disease have occurred mainly in the Amazon region during the last ten years. With geographical limitations, OROV causing persistent endemicity and periodic outbreaks are reported in both rural and urban communities in Brazil, the Plurinational State of Bolivia, Cuba, Colombia, Ecuador, French Guiana, Panama, Peru, and Trinidad and Tobago. The ongoing outbreak highlights the need to strengthen epidemiological and entomological surveillance and to reinforce preventive measures in the population. This is crucial due to the (C1) potential expansion of the virus's transmission area (C1) and the (C1) growing understanding of the disease spectrum (C1), including possible new transmission routes, and possible new vectors that could affect both the general population and vulnerable groups, such as pregnant women, their fetuses, and newborns. Based on available information, WHO assesses the (E1) overall public health risk posed by this virus to be high at the regional level (E1) and low at the global level.",disease knowledge,health risk
2024-DON530,,,No relevant causality,.,No context,No context
2024-DON529,favorable conditions for vector populations during the monsoon season in affected areas,rapid symptom onset and high case-fatality ratio,T1,"Although previous outbreaks have been reported in India, this outbreak is considered the largest in the past 20 years. While authorities are making efforts to control the transmission of CHPV, further transmission of CHPV is possible in the coming weeks, considering the (C1) favorable conditions for vector populations during the monsoon season in affected areas (C1). CHPV infection causes a (E1) rapid symptom onset (E1) and a (E1) high case-fatality ratio (56-75%) (E1). There is no specific treatment or vaccine available, and management is symptomatic; timely referral of suspected AES cases to designated facilities can improve outcomes. CHPV infection can cause (E2) epidemics (E2) with a (E3) substantial demand on public health systems (E3), including surveillance, case management, infection prevention and control, and laboratory capacity to diagnose CHPV infection.",environmental factors,disease severity
2024-DON529,favorable conditions for vector populations during the monsoon season in affected areas,epidemics,T1,"Although previous outbreaks have been reported in India, this outbreak is considered the largest in the past 20 years. While authorities are making efforts to control the transmission of CHPV, further transmission of CHPV is possible in the coming weeks, considering the (C1) favorable conditions for vector populations during the monsoon season in affected areas (C1). CHPV infection causes a (E1) rapid symptom onset (E1) and a (E1) high case-fatality ratio (56-75%) (E1). There is no specific treatment or vaccine available, and management is symptomatic; timely referral of suspected AES cases to designated facilities can improve outcomes. CHPV infection can cause (E2) epidemics (E2) with a (E3) substantial demand on public health systems (E3), including surveillance, case management, infection prevention and control, and laboratory capacity to diagnose CHPV infection.",environmental factors,disease outbreaks
2024-DON529,,,No causality,WHO assessed the risk as moderate at the national level based on above considerations. The risk assessment will be reviewed as the situation of the outbreak evolves.,No context,No context
2024-DON528,exclusive human-to-human transmission,expansion of mpox in the African continent,T1,"The current expansion of mpox in the African continent is unprecedented. At least four countries have identified cases for the first time and others, such as Côte d'Ivoire, are reporting re-emerging outbreaks. The modes of transmission in these countries are not fully described yet and are likely to include (C1) exclusive human-to-human transmission (C1). Clade I mpox is being identified for the first time outside of the countries that had been previously affected.",disease transmission,disease spread
2024-DON528,travel to or from the Democratic Republic of Congo,sustained community transmission,T1,"Initial transmission in the newly affected countries in East Africa and beyond has been linked to (C1) travel to or from the Democratic Republic of Congo (C1), but the expansion of the outbreak in Burundi suggests that in some settings, there may already be (E1) sustained community transmission (E1). Epidemiological links between confirmed cases are not always known, therefore, (E2) multiple transmission chains (E2) might be ongoing in the different countries, and more undetected cases in the community are likely. Based on available epidemiological data, this clade has been spreading rapidly among adults through (C2) close physical contact (C2), including (C2) sexual contact identified within networks of sex workers and their clients (C2).",travel exposure,disease spread
2024-DON528,close physical contact,multiple transmission chains,T1,"Initial transmission in the newly affected countries in East Africa and beyond has been linked to (C1) travel to or from the Democratic Republic of Congo (C1), but the expansion of the outbreak in Burundi suggests that in some settings, there may already be (E1) sustained community transmission (E1). Epidemiological links between confirmed cases are not always known, therefore, (E2) multiple transmission chains (E2) might be ongoing in the different countries, and more undetected cases in the community are likely. Based on available epidemiological data, this clade has been spreading rapidly among adults through (C2) close physical contact (C2), including (C2) sexual contact identified within networks of sex workers and their clients (C2).",contact transmission,disease spread
2024-DON528,sexual contact identified within networks of sex workers and their clients,multiple transmission chains,T1,"Initial transmission in the newly affected countries in East Africa and beyond has been linked to (C1) travel to or from the Democratic Republic of Congo (C1), but the expansion of the outbreak in Burundi suggests that in some settings, there may already be (E1) sustained community transmission (E1). Epidemiological links between confirmed cases are not always known, therefore, (E2) multiple transmission chains (E2) might be ongoing in the different countries, and more undetected cases in the community are likely. Based on available epidemiological data, this clade has been spreading rapidly among adults through (C2) close physical contact (C2), including (C2) sexual contact identified within networks of sex workers and their clients (C2).",contact transmission,disease spread
2024-DON528,high population density,explosive outbreaks,T3,"As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. In areas or congregate settings with (C1) high population density (C1) as well in (C1) high-risk sexual networks (C1), transmission could lead to (E1) explosive outbreaks (E1), further compounded by (C2) population movements (C2) or (C2) insecurity (C2). Conversely, the virus can also spread silently along commercial travel routes as in some cases (C3) symptoms may be less severe (C3), (C3) access to health services in transit may be limited (C3) or (C3) concerns about stigma (C3) may cause persons affected to avoid seeking care. While vaccination against smallpox was shown in the past to be cross-protective against mpox, any immunity from smallpox vaccination will only be present in persons over the age of 42 to 50 years or older, since natural exposure to smallpox and smallpox vaccination programmes ended in 1980 after smallpox eradication. None of the four newly affected countries has access to mpox vaccines or antivirals. Based on the above, WHO has separately assessed the risk of mpox in the eastern Democratic Republic of the Congo and neighbouring countries as high and in Cote d’Ivoire, and other West African countries as moderate.",population density,disease spread
2024-DON528,high-risk sexual networks,explosive outbreaks,T3,"As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. In areas or congregate settings with (C1) high population density (C1) as well in (C1) high-risk sexual networks (C1), transmission could lead to (E1) explosive outbreaks (E1), further compounded by (C2) population movements (C2) or (C2) insecurity (C2). Conversely, the virus can also spread silently along commercial travel routes as in some cases (C3) symptoms may be less severe (C3), (C3) access to health services in transit may be limited (C3) or (C3) concerns about stigma (C3) may cause persons affected to avoid seeking care. While vaccination against smallpox was shown in the past to be cross-protective against mpox, any immunity from smallpox vaccination will only be present in persons over the age of 42 to 50 years or older, since natural exposure to smallpox and smallpox vaccination programmes ended in 1980 after smallpox eradication. None of the four newly affected countries has access to mpox vaccines or antivirals. Based on the above, WHO has separately assessed the risk of mpox in the eastern Democratic Republic of the Congo and neighbouring countries as high and in Cote d’Ivoire, and other West African countries as moderate.",behavioral risks,disease spread
2024-DON528,population movements,explosive outbreaks,T3,"As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. In areas or congregate settings with (C1) high population density (C1) as well in (C1) high-risk sexual networks (C1), transmission could lead to (E1) explosive outbreaks (E1), further compounded by (C2) population movements (C2) or (C2) insecurity (C2). Conversely, the virus can also spread silently along commercial travel routes as in some cases (C3) symptoms may be less severe (C3), (C3) access to health services in transit may be limited (C3) or (C3) concerns about stigma (C3) may cause persons affected to avoid seeking care. While vaccination against smallpox was shown in the past to be cross-protective against mpox, any immunity from smallpox vaccination will only be present in persons over the age of 42 to 50 years or older, since natural exposure to smallpox and smallpox vaccination programmes ended in 1980 after smallpox eradication. None of the four newly affected countries has access to mpox vaccines or antivirals. Based on the above, WHO has separately assessed the risk of mpox in the eastern Democratic Republic of the Congo and neighbouring countries as high and in Cote d’Ivoire, and other West African countries as moderate.",migration trends,disease spread
2024-DON528,insecurity,explosive outbreaks,T3,"As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. In areas or congregate settings with (C1) high population density (C1) as well in (C1) high-risk sexual networks (C1), transmission could lead to (E1) explosive outbreaks (E1), further compounded by (C2) population movements (C2) or (C2) insecurity (C2). Conversely, the virus can also spread silently along commercial travel routes as in some cases (C3) symptoms may be less severe (C3), (C3) access to health services in transit may be limited (C3) or (C3) concerns about stigma (C3) may cause persons affected to avoid seeking care. While vaccination against smallpox was shown in the past to be cross-protective against mpox, any immunity from smallpox vaccination will only be present in persons over the age of 42 to 50 years or older, since natural exposure to smallpox and smallpox vaccination programmes ended in 1980 after smallpox eradication. None of the four newly affected countries has access to mpox vaccines or antivirals. Based on the above, WHO has separately assessed the risk of mpox in the eastern Democratic Republic of the Congo and neighbouring countries as high and in Cote d’Ivoire, and other West African countries as moderate.",social unrest,disease spread
2024-DON528,symptoms may be less severe,virus can spread silently,T3,"As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. In areas or congregate settings with (C1) high population density (C1) as well in (C1) high-risk sexual networks (C1), transmission could lead to (E1) explosive outbreaks (E1), further compounded by (C2) population movements (C2) or (C2) insecurity (C2). Conversely, the virus can also spread silently along commercial travel routes as in some cases (C3) symptoms may be less severe (C3), (C3) access to health services in transit may be limited (C3) or (C3) concerns about stigma (C3) may cause persons affected to avoid seeking care. While vaccination against smallpox was shown in the past to be cross-protective against mpox, any immunity from smallpox vaccination will only be present in persons over the age of 42 to 50 years or older, since natural exposure to smallpox and smallpox vaccination programmes ended in 1980 after smallpox eradication. None of the four newly affected countries has access to mpox vaccines or antivirals. Based on the above, WHO has separately assessed the risk of mpox in the eastern Democratic Republic of the Congo and neighbouring countries as high and in Cote d’Ivoire, and other West African countries as moderate.",disease severity,silent transmission
2024-DON528,access to health services in transit may be limited,virus can spread silently,T3,"As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. In areas or congregate settings with (C1) high population density (C1) as well in (C1) high-risk sexual networks (C1), transmission could lead to (E1) explosive outbreaks (E1), further compounded by (C2) population movements (C2) or (C2) insecurity (C2). Conversely, the virus can also spread silently along commercial travel routes as in some cases (C3) symptoms may be less severe (C3), (C3) access to health services in transit may be limited (C3) or (C3) concerns about stigma (C3) may cause persons affected to avoid seeking care. While vaccination against smallpox was shown in the past to be cross-protective against mpox, any immunity from smallpox vaccination will only be present in persons over the age of 42 to 50 years or older, since natural exposure to smallpox and smallpox vaccination programmes ended in 1980 after smallpox eradication. None of the four newly affected countries has access to mpox vaccines or antivirals. Based on the above, WHO has separately assessed the risk of mpox in the eastern Democratic Republic of the Congo and neighbouring countries as high and in Cote d’Ivoire, and other West African countries as moderate.",healthcare access,silent transmission
2024-DON528,concerns about stigma,virus can spread silently,T3,"As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. In areas or congregate settings with (C1) high population density (C1) as well in (C1) high-risk sexual networks (C1), transmission could lead to (E1) explosive outbreaks (E1), further compounded by (C2) population movements (C2) or (C2) insecurity (C2). Conversely, the virus can also spread silently along commercial travel routes as in some cases (C3) symptoms may be less severe (C3), (C3) access to health services in transit may be limited (C3) or (C3) concerns about stigma (C3) may cause persons affected to avoid seeking care. While vaccination against smallpox was shown in the past to be cross-protective against mpox, any immunity from smallpox vaccination will only be present in persons over the age of 42 to 50 years or older, since natural exposure to smallpox and smallpox vaccination programmes ended in 1980 after smallpox eradication. None of the four newly affected countries has access to mpox vaccines or antivirals. Based on the above, WHO has separately assessed the risk of mpox in the eastern Democratic Republic of the Congo and neighbouring countries as high and in Cote d’Ivoire, and other West African countries as moderate.",social concerns,silent transmission
2024-DON528,under-detection and under-reporting of local transmission,mpox outbreak in Africa will continue to evolve,T1,"This risk applies to the general population, especially those who have sexual contact with a mpox case, as well as health workers if they are not taking appropriate precautions when examining, testing and treating mpox cases. Currently no deaths have been reported in the five above mentioned countries, however, there is the potential for increased health impact with wider spread among vulnerable groups such as children, immunocompromised individuals, including persons with uncontrolled HIV infection or advanced HIV disease, or pregnant women in whom mpox can be more severe. There is concern that the mpox outbreak in Africa will continue to evolve given: The evidence of possible (C1) under-detection and under-reporting of local transmission (C1). Many reported cases have no established epidemiological link and have been identified in different countries and in different locations within each country. While all of the governments have activated emergency responses in the countries, with support from in-country and global partners, resources to respond remain limited in some of the countries, and (C2) resource mobilization may be slow (C2). Technical and financial support is needed to ensure a robust response at national and provincial/local levels. Although the governments and partners are all mobilized to support adequate patient care for affected patients and introduce vaccines for people at risk, these measures are currently not in place in most countries in Africa, and their acquisition and roll-out will still require some time for implementation. Since some of the countries have not reported mpox before, (C3) public awareness of the disease (C3), as well as (C3) knowledge about and capacity for identifying it among health and care workers in newly affected countries remains limited (C3). Concurrently, the global multi-country outbreak of mpox is still ongoing.",detection issues,disease evolution
2024-DON528,resource mobilization may be slow,limited resources to respond,T1,"This risk applies to the general population, especially those who have sexual contact with a mpox case, as well as health workers if they are not taking appropriate precautions when examining, testing and treating mpox cases. Currently no deaths have been reported in the five above mentioned countries, however, there is the potential for increased health impact with wider spread among vulnerable groups such as children, immunocompromised individuals, including persons with uncontrolled HIV infection or advanced HIV disease, or pregnant women in whom mpox can be more severe. There is concern that the mpox outbreak in Africa will continue to evolve given: The evidence of possible (C1) under-detection and under-reporting of local transmission (C1). Many reported cases have no established epidemiological link and have been identified in different countries and in different locations within each country. While all of the governments have activated emergency responses in the countries, with support from in-country and global partners, resources to respond remain limited in some of the countries, and (C2) resource mobilization may be slow (C2). Technical and financial support is needed to ensure a robust response at national and provincial/local levels. Although the governments and partners are all mobilized to support adequate patient care for affected patients and introduce vaccines for people at risk, these measures are currently not in place in most countries in Africa, and their acquisition and roll-out will still require some time for implementation. Since some of the countries have not reported mpox before, (C3) public awareness of the disease (C3), as well as (C3) knowledge about and capacity for identifying it among health and care workers in newly affected countries remains limited (C3). Concurrently, the global multi-country outbreak of mpox is still ongoing.",funding challenges,resource scarcity
2024-DON528,limited public awareness of the disease and knowledge about and capacity for identifying it among health and care workers,mpox outbreak in Africa will continue to evolve,T1,"This risk applies to the general population, especially those who have sexual contact with a mpox case, as well as health workers if they are not taking appropriate precautions when examining, testing and treating mpox cases. Currently no deaths have been reported in the five above mentioned countries, however, there is the potential for increased health impact with wider spread among vulnerable groups such as children, immunocompromised individuals, including persons with uncontrolled HIV infection or advanced HIV disease, or pregnant women in whom mpox can be more severe. There is concern that the mpox outbreak in Africa will continue to evolve given: The evidence of possible (C1) under-detection and under-reporting of local transmission (C1). Many reported cases have no established epidemiological link and have been identified in different countries and in different locations within each country. While all of the governments have activated emergency responses in the countries, with support from in-country and global partners, resources to respond remain limited in some of the countries, and (C2) resource mobilization may be slow (C2). Technical and financial support is needed to ensure a robust response at national and provincial/local levels. Although the governments and partners are all mobilized to support adequate patient care for affected patients and introduce vaccines for people at risk, these measures are currently not in place in most countries in Africa, and their acquisition and roll-out will still require some time for implementation. Since some of the countries have not reported mpox before, (C3) public awareness of the disease (C3), as well as (C3) knowledge about and capacity for identifying it among health and care workers in newly affected countries remains limited (C3). Concurrently, the global multi-country outbreak of mpox is still ongoing.",awareness deficiency,disease evolution
2024-DON528,increase of cases and reporting countries,risk of further transmission in the region and the whole world,T1,"Countries outside of Africa that seemed to have achieved control of human-to-human transmission continue to detect sporadic cases and outbreaks, and an unprecedented (C1) increase of cases and reporting countries (C1) has been observed in the African Region, especially in the Democratic Republic of the Congo, increasing the (E1) risk of further transmission in the region and the whole world (E1).",disease spread,global transmission
2024-DON527,available laboratory capacity to perform genomic sequencing tests or analysis of specific markers,prevalence of hvKp-associated infections may be underestimated,T1,"Globally, there is no systematic surveillance that allows for the routine identification and information collection of hvKp strains. Identification of hvKp is challenging given that it is determined by (C1) available laboratory capacity to perform genomic sequencing tests or analysis of specific markers that may indicate hypervirulence (C1), so the (E1) prevalence of hvKp-associated infections may be underestimated (E1). Assessing the current risk of hvKp at the global level aims to incorporate several risk components including 1) the (E2) emergence and sustained transmission of hvKp carrying carbapenem resistance genes (E2), considering the public health impact of the identified resistance for the AMR related events; 2) the (E3) risk of geographical spread (E3); 3) the (E4) risk of insufficient control capacities with available resources (E4); and 4) the (E5) risk of resistance spread to other bacterial species via mobile genetic elements (E5). The risk at the global level is assessed as moderate considering that: (C2) Infections caused by hvKp traditionally have occurred within communities in certain geographical regions (Asia) and are associated with high morbidity and mortality as well as high pathogenicity and limited antibiotic choices (C2). However, recent reports from the WHO European region and the European Centre for Disease Prevention and Control (ECDC) have shown (E6) transmission in health-care settings (E6), and several studies from China have reported (E6) clusters of health care-associated infections of hvKp (E6); hence highlighting the importance of (C3) strict infection prevention and control (IPC) measures (C3) when managing these cases in health-care settings.",diagnostic capacity,disease underestimation
2024-DON527,Infections caused by hvKp traditionally have occurred within communities in certain geographical regions (Asia) and are associated with high morbidity and mortality as well as high pathogenicity and limited antibiotic choices,transmission in health-care settings,T1,"Globally, there is no systematic surveillance that allows for the routine identification and information collection of hvKp strains. Identification of hvKp is challenging given that it is determined by (C1) available laboratory capacity to perform genomic sequencing tests or analysis of specific markers that may indicate hypervirulence (C1), so the (E1) prevalence of hvKp-associated infections may be underestimated (E1). Assessing the current risk of hvKp at the global level aims to incorporate several risk components including 1) the (E2) emergence and sustained transmission of hvKp carrying carbapenem resistance genes (E2), considering the public health impact of the identified resistance for the AMR related events; 2) the (E3) risk of geographical spread (E3); 3) the (E4) risk of insufficient control capacities with available resources (E4); and 4) the (E5) risk of resistance spread to other bacterial species via mobile genetic elements (E5). The risk at the global level is assessed as moderate considering that: (C2) Infections caused by hvKp traditionally have occurred within communities in certain geographical regions (Asia) and are associated with high morbidity and mortality as well as high pathogenicity and limited antibiotic choices (C2). However, recent reports from the WHO European region and the European Centre for Disease Prevention and Control (ECDC) have shown (E6) transmission in health-care settings (E6), and several studies from China have reported (E6) clusters of health care-associated infections of hvKp (E6); hence highlighting the importance of (C3) strict infection prevention and control (IPC) measures (C3) when managing these cases in health-care settings.",regional infections,healthcare transmission
2024-DON527,strict infection prevention and control (IPC) measures,transmission in health-care settings,T1,"Globally, there is no systematic surveillance that allows for the routine identification and information collection of hvKp strains. Identification of hvKp is challenging given that it is determined by (C1) available laboratory capacity to perform genomic sequencing tests or analysis of specific markers that may indicate hypervirulence (C1), so the (E1) prevalence of hvKp-associated infections may be underestimated (E1). Assessing the current risk of hvKp at the global level aims to incorporate several risk components including 1) the (E2) emergence and sustained transmission of hvKp carrying carbapenem resistance genes (E2), considering the public health impact of the identified resistance for the AMR related events; 2) the (E3) risk of geographical spread (E3); 3) the (E4) risk of insufficient control capacities with available resources (E4); and 4) the (E5) risk of resistance spread to other bacterial species via mobile genetic elements (E5). The risk at the global level is assessed as moderate considering that: (C2) Infections caused by hvKp traditionally have occurred within communities in certain geographical regions (Asia) and are associated with high morbidity and mortality as well as high pathogenicity and limited antibiotic choices (C2). However, recent reports from the WHO European region and the European Centre for Disease Prevention and Control (ECDC) have shown (E6) transmission in health-care settings (E6), and several studies from China have reported (E6) clusters of health care-associated infections of hvKp (E6); hence highlighting the importance of (C3) strict infection prevention and control (IPC) measures (C3) when managing these cases in health-care settings.",disease prevention,healthcare transmission
2024-DON527,hypervirulence and antibiotic resistance,increased risk of spread of these strains,T1,"With the concurrence of (C1) hypervirulence and antibiotic resistance (C1), it is expected that there will be an (E1) increased risk of spread of these strains at both the community and hospital levels (E1). As with other resistance mechanisms, the (E2) risk of spread (E2) could increase due to (C2) high movements of people (within and between countries and regions) (C2). There are very limited antimicrobial treatment options for the carbapenem-resistant hvKp isolates and these strains have the capacity to generate outbreaks. The (C3) high conjugation capacity of the carbapenem-resistant hvKp (CR-hvKp) (C3) and the potential for further dissemination in clinical settings; hvKp ST23 particularly out-competes other gut bacteria facilitating (E3) colonization and spread (E3). Detection of the emergence of multi-resistant or extensively resistant pathogens requires established resistance laboratory surveillance systems as well as effective infection prevention and control programs in health-care facilities. (C4) Lack of laboratory capacity (C4) contributes to the (E4) restriction of laboratory diagnosis (E4), and this affects the sensitivity of the surveillance. Most affected countries do not have the capacity for diagnosis in the clinical setting as the laboratory diagnosis of hvKp infections depends on the availability of molecular tests. There is global heterogeneity in laboratory surveillance capacity for this pathogen; because of this, there is no systematic surveillance (detection, monitoring, and reporting) of hvKp infections in most countries or regions. Outbreaks and cases are documented in a non-systematic way through laboratory surveillance for antimicrobial resistance, or retrospective epidemiological studies, making (E5) data on the prevalence of hvKp infections scarce (E5). The prevention and control of carbapenem-resistant hvKp poses significant challenges because it has not been possible to establish the extent of its dissemination in the countries of the different regions and information on this subject is currently limited. The level of confidence in the available information and risk assessment at the global level is moderate given the challenges with surveillance, lack of information on laboratory testing rates, ability to track and determine scale of community transmission, the gap in the available data on infections, hospitalization and from the overall burden of the disease.",pathogen traits,disease spread
2024-DON527,high movements of people,risk of spread,T1,"With the concurrence of (C1) hypervirulence and antibiotic resistance (C1), it is expected that there will be an (E1) increased risk of spread of these strains at both the community and hospital levels (E1). As with other resistance mechanisms, the (E2) risk of spread (E2) could increase due to (C2) high movements of people (within and between countries and regions) (C2). There are very limited antimicrobial treatment options for the carbapenem-resistant hvKp isolates and these strains have the capacity to generate outbreaks. The (C3) high conjugation capacity of the carbapenem-resistant hvKp (CR-hvKp) (C3) and the potential for further dissemination in clinical settings; hvKp ST23 particularly out-competes other gut bacteria facilitating (E3) colonization and spread (E3). Detection of the emergence of multi-resistant or extensively resistant pathogens requires established resistance laboratory surveillance systems as well as effective infection prevention and control programs in health-care facilities. (C4) Lack of laboratory capacity (C4) contributes to the (E4) restriction of laboratory diagnosis (E4), and this affects the sensitivity of the surveillance. Most affected countries do not have the capacity for diagnosis in the clinical setting as the laboratory diagnosis of hvKp infections depends on the availability of molecular tests. There is global heterogeneity in laboratory surveillance capacity for this pathogen; because of this, there is no systematic surveillance (detection, monitoring, and reporting) of hvKp infections in most countries or regions. Outbreaks and cases are documented in a non-systematic way through laboratory surveillance for antimicrobial resistance, or retrospective epidemiological studies, making (E5) data on the prevalence of hvKp infections scarce (E5). The prevention and control of carbapenem-resistant hvKp poses significant challenges because it has not been possible to establish the extent of its dissemination in the countries of the different regions and information on this subject is currently limited. The level of confidence in the available information and risk assessment at the global level is moderate given the challenges with surveillance, lack of information on laboratory testing rates, ability to track and determine scale of community transmission, the gap in the available data on infections, hospitalization and from the overall burden of the disease.",population mobility,spread risk
2024-DON527,high conjugation capacity of the carbapenem-resistant hvKp,colonization and spread,T1,"With the concurrence of (C1) hypervirulence and antibiotic resistance (C1), it is expected that there will be an (E1) increased risk of spread of these strains at both the community and hospital levels (E1). As with other resistance mechanisms, the (E2) risk of spread (E2) could increase due to (C2) high movements of people (within and between countries and regions) (C2). There are very limited antimicrobial treatment options for the carbapenem-resistant hvKp isolates and these strains have the capacity to generate outbreaks. The (C3) high conjugation capacity of the carbapenem-resistant hvKp (CR-hvKp) (C3) and the potential for further dissemination in clinical settings; hvKp ST23 particularly out-competes other gut bacteria facilitating (E3) colonization and spread (E3). Detection of the emergence of multi-resistant or extensively resistant pathogens requires established resistance laboratory surveillance systems as well as effective infection prevention and control programs in health-care facilities. (C4) Lack of laboratory capacity (C4) contributes to the (E4) restriction of laboratory diagnosis (E4), and this affects the sensitivity of the surveillance. Most affected countries do not have the capacity for diagnosis in the clinical setting as the laboratory diagnosis of hvKp infections depends on the availability of molecular tests. There is global heterogeneity in laboratory surveillance capacity for this pathogen; because of this, there is no systematic surveillance (detection, monitoring, and reporting) of hvKp infections in most countries or regions. Outbreaks and cases are documented in a non-systematic way through laboratory surveillance for antimicrobial resistance, or retrospective epidemiological studies, making (E5) data on the prevalence of hvKp infections scarce (E5). The prevention and control of carbapenem-resistant hvKp poses significant challenges because it has not been possible to establish the extent of its dissemination in the countries of the different regions and information on this subject is currently limited. The level of confidence in the available information and risk assessment at the global level is moderate given the challenges with surveillance, lack of information on laboratory testing rates, ability to track and determine scale of community transmission, the gap in the available data on infections, hospitalization and from the overall burden of the disease.",antibiotic resistance,population dynamics
2024-DON527,Lack of laboratory capacity,restriction of laboratory diagnosis,T1,"With the concurrence of (C1) hypervirulence and antibiotic resistance (C1), it is expected that there will be an (E1) increased risk of spread of these strains at both the community and hospital levels (E1). As with other resistance mechanisms, the (E2) risk of spread (E2) could increase due to (C2) high movements of people (within and between countries and regions) (C2). There are very limited antimicrobial treatment options for the carbapenem-resistant hvKp isolates and these strains have the capacity to generate outbreaks. The (C3) high conjugation capacity of the carbapenem-resistant hvKp (CR-hvKp) (C3) and the potential for further dissemination in clinical settings; hvKp ST23 particularly out-competes other gut bacteria facilitating (E3) colonization and spread (E3). Detection of the emergence of multi-resistant or extensively resistant pathogens requires established resistance laboratory surveillance systems as well as effective infection prevention and control programs in health-care facilities. (C4) Lack of laboratory capacity (C4) contributes to the (E4) restriction of laboratory diagnosis (E4), and this affects the sensitivity of the surveillance. Most affected countries do not have the capacity for diagnosis in the clinical setting as the laboratory diagnosis of hvKp infections depends on the availability of molecular tests. There is global heterogeneity in laboratory surveillance capacity for this pathogen; because of this, there is no systematic surveillance (detection, monitoring, and reporting) of hvKp infections in most countries or regions. Outbreaks and cases are documented in a non-systematic way through laboratory surveillance for antimicrobial resistance, or retrospective epidemiological studies, making (E5) data on the prevalence of hvKp infections scarce (E5). The prevention and control of carbapenem-resistant hvKp poses significant challenges because it has not been possible to establish the extent of its dissemination in the countries of the different regions and information on this subject is currently limited. The level of confidence in the available information and risk assessment at the global level is moderate given the challenges with surveillance, lack of information on laboratory testing rates, ability to track and determine scale of community transmission, the gap in the available data on infections, hospitalization and from the overall burden of the disease.",healthcare limitations,diagnostic limitations
2024-DON526,presence of the vector in the country,Aedes aegypti and Aedes albopictus are present in the provinces,T1,"This represents the first report of autochthonous dengue cases ever documented in Iran. The confirmation of local dengue transmission in 2024 is thus an atypical yet foreseeable event due to the (C1) presence of the vector in the country (C1) and the (C1) movement of people from endemic areas to Iran (C1). Based on entomological surveillance, to date, (E1) Aedes aegypti and Aedes albopictus are present in the provinces of Baluchistan, Bushehr, Fars, Gilan, Golestan, Hormozgan, Khuzestan, Mazandaran and Sistan (E1). On 16 May 2024, WHO reassessed the global risk of dengue, confirming it to be high and emphasizing that dengue continues to pose a significant public health threat worldwide. The national risk for Iran is also high due to the (C2) presence of the vector in the country (C2), (C2) favorable climate conditions for the competent vector (C2) and the (C2) movement of people from countries experiencing ongoing outbreaks and endemic areas to Iran (C2). There is heightened awareness of the potential increase in importations and subsequent (E2) transmission of the disease (E2) during the upcoming Arbaeen pilgrimage in August, when millions of people from different countries, including countries reporting dengue cases travel to Iran.",vector presence,mosquito presence
2024-DON526,movement of people from endemic areas to Iran,Aedes aegypti and Aedes albopictus are present in the provinces,T1,"This represents the first report of autochthonous dengue cases ever documented in Iran. The confirmation of local dengue transmission in 2024 is thus an atypical yet foreseeable event due to the (C1) presence of the vector in the country (C1) and the (C1) movement of people from endemic areas to Iran (C1). Based on entomological surveillance, to date, (E1) Aedes aegypti and Aedes albopictus are present in the provinces of Baluchistan, Bushehr, Fars, Gilan, Golestan, Hormozgan, Khuzestan, Mazandaran and Sistan (E1). On 16 May 2024, WHO reassessed the global risk of dengue, confirming it to be high and emphasizing that dengue continues to pose a significant public health threat worldwide. The national risk for Iran is also high due to the (C2) presence of the vector in the country (C2), (C2) favorable climate conditions for the competent vector (C2) and the (C2) movement of people from countries experiencing ongoing outbreaks and endemic areas to Iran (C2). There is heightened awareness of the potential increase in importations and subsequent (E2) transmission of the disease (E2) during the upcoming Arbaeen pilgrimage in August, when millions of people from different countries, including countries reporting dengue cases travel to Iran.",migration patterns,mosquito presence
2024-DON526,presence of the vector in the country,transmission of the disease,T3,"This represents the first report of autochthonous dengue cases ever documented in Iran. The confirmation of local dengue transmission in 2024 is thus an atypical yet foreseeable event due to the (C1) presence of the vector in the country (C1) and the (C1) movement of people from endemic areas to Iran (C1). Based on entomological surveillance, to date, (E1) Aedes aegypti and Aedes albopictus are present in the provinces of Baluchistan, Bushehr, Fars, Gilan, Golestan, Hormozgan, Khuzestan, Mazandaran and Sistan (E1). On 16 May 2024, WHO reassessed the global risk of dengue, confirming it to be high and emphasizing that dengue continues to pose a significant public health threat worldwide. The national risk for Iran is also high due to the (C2) presence of the vector in the country (C2), (C2) favorable climate conditions for the competent vector (C2) and the (C2) movement of people from countries experiencing ongoing outbreaks and endemic areas to Iran (C2). There is heightened awareness of the potential increase in importations and subsequent (E2) transmission of the disease (E2) during the upcoming Arbaeen pilgrimage in August, when millions of people from different countries, including countries reporting dengue cases travel to Iran.",vector presence,disease transmission
2024-DON526,favorable climate conditions for the competent vector,transmission of the disease,T3,"This represents the first report of autochthonous dengue cases ever documented in Iran. The confirmation of local dengue transmission in 2024 is thus an atypical yet foreseeable event due to the (C1) presence of the vector in the country (C1) and the (C1) movement of people from endemic areas to Iran (C1). Based on entomological surveillance, to date, (E1) Aedes aegypti and Aedes albopictus are present in the provinces of Baluchistan, Bushehr, Fars, Gilan, Golestan, Hormozgan, Khuzestan, Mazandaran and Sistan (E1). On 16 May 2024, WHO reassessed the global risk of dengue, confirming it to be high and emphasizing that dengue continues to pose a significant public health threat worldwide. The national risk for Iran is also high due to the (C2) presence of the vector in the country (C2), (C2) favorable climate conditions for the competent vector (C2) and the (C2) movement of people from countries experiencing ongoing outbreaks and endemic areas to Iran (C2). There is heightened awareness of the potential increase in importations and subsequent (E2) transmission of the disease (E2) during the upcoming Arbaeen pilgrimage in August, when millions of people from different countries, including countries reporting dengue cases travel to Iran.",climate influence,disease transmission
2024-DON526,movement of people from countries experiencing ongoing outbreaks and endemic areas to Iran,transmission of the disease,T3,"This represents the first report of autochthonous dengue cases ever documented in Iran. The confirmation of local dengue transmission in 2024 is thus an atypical yet foreseeable event due to the (C1) presence of the vector in the country (C1) and the (C1) movement of people from endemic areas to Iran (C1). Based on entomological surveillance, to date, (E1) Aedes aegypti and Aedes albopictus are present in the provinces of Baluchistan, Bushehr, Fars, Gilan, Golestan, Hormozgan, Khuzestan, Mazandaran and Sistan (E1). On 16 May 2024, WHO reassessed the global risk of dengue, confirming it to be high and emphasizing that dengue continues to pose a significant public health threat worldwide. The national risk for Iran is also high due to the (C2) presence of the vector in the country (C2), (C2) favorable climate conditions for the competent vector (C2) and the (C2) movement of people from countries experiencing ongoing outbreaks and endemic areas to Iran (C2). There is heightened awareness of the potential increase in importations and subsequent (E2) transmission of the disease (E2) during the upcoming Arbaeen pilgrimage in August, when millions of people from different countries, including countries reporting dengue cases travel to Iran.",travel transmission,disease transmission
2024-DON525,lack of early clinical recognition of an infection,community transmission,T3,"The sudden appearance of unlinked cases of mpox in South Africa without a history of international travel, the high HIV prevalence among confirmed cases, and the high case fatality ratio suggest that (E1) community transmission (E1) is underway, and the cases detected to date represent a small proportion of all mpox cases that might be occurring in the community; it is unknown how long the virus may have been circulating. This may in part be due to the (C1) lack of early clinical recognition of an infection (C1) with which South Africa previously gained little experience during the ongoing global outbreak, potential (C1) pauci-symptomatic manifestation of the disease (C1), or (C1, E2) delays in care-seeking behaviour (C1, E2) due to (C2) limited access to care (C2) or (C2) fear of stigma (C2). At present, most of the transmission in the initial cases is linked to (C3) recent sexual contacts among men (C3), similar to the spread in newly affected countries during the 2022-2024 multi-country outbreak. For most confirmed cases, no epidemiological link has been established, possibly due in part to (C4) incomplete contact identification (C4).",diagnostic delay,disease spread
2024-DON525,pauci-symptomatic manifestation of the disease,community transmission,T3,"The sudden appearance of unlinked cases of mpox in South Africa without a history of international travel, the high HIV prevalence among confirmed cases, and the high case fatality ratio suggest that (E1) community transmission (E1) is underway, and the cases detected to date represent a small proportion of all mpox cases that might be occurring in the community; it is unknown how long the virus may have been circulating. This may in part be due to the (C1) lack of early clinical recognition of an infection (C1) with which South Africa previously gained little experience during the ongoing global outbreak, potential (C1) pauci-symptomatic manifestation of the disease (C1), or (C1, E2) delays in care-seeking behaviour (C1, E2) due to (C2) limited access to care (C2) or (C2) fear of stigma (C2). At present, most of the transmission in the initial cases is linked to (C3) recent sexual contacts among men (C3), similar to the spread in newly affected countries during the 2022-2024 multi-country outbreak. For most confirmed cases, no epidemiological link has been established, possibly due in part to (C4) incomplete contact identification (C4).",disease symptoms,disease spread
2024-DON525,delays in care-seeking behaviour,community transmission,T3,"The sudden appearance of unlinked cases of mpox in South Africa without a history of international travel, the high HIV prevalence among confirmed cases, and the high case fatality ratio suggest that (E1) community transmission (E1) is underway, and the cases detected to date represent a small proportion of all mpox cases that might be occurring in the community; it is unknown how long the virus may have been circulating. This may in part be due to the (C1) lack of early clinical recognition of an infection (C1) with which South Africa previously gained little experience during the ongoing global outbreak, potential (C1) pauci-symptomatic manifestation of the disease (C1), or (C1, E2) delays in care-seeking behaviour (C1, E2) due to (C2) limited access to care (C2) or (C2) fear of stigma (C2). At present, most of the transmission in the initial cases is linked to (C3) recent sexual contacts among men (C3), similar to the spread in newly affected countries during the 2022-2024 multi-country outbreak. For most confirmed cases, no epidemiological link has been established, possibly due in part to (C4) incomplete contact identification (C4).",healthcare delays,disease spread
2024-DON525,limited access to care,delays in care-seeking behaviour,T4,"The sudden appearance of unlinked cases of mpox in South Africa without a history of international travel, the high HIV prevalence among confirmed cases, and the high case fatality ratio suggest that (E1) community transmission (E1) is underway, and the cases detected to date represent a small proportion of all mpox cases that might be occurring in the community; it is unknown how long the virus may have been circulating. This may in part be due to the (C1) lack of early clinical recognition of an infection (C1) with which South Africa previously gained little experience during the ongoing global outbreak, potential (C1) pauci-symptomatic manifestation of the disease (C1), or (C1, E2) delays in care-seeking behaviour (C1, E2) due to (C2) limited access to care (C2) or (C2) fear of stigma (C2). At present, most of the transmission in the initial cases is linked to (C3) recent sexual contacts among men (C3), similar to the spread in newly affected countries during the 2022-2024 multi-country outbreak. For most confirmed cases, no epidemiological link has been established, possibly due in part to (C4) incomplete contact identification (C4).",healthcare barriers,healthcare delays
2024-DON525,fear of stigma,delays in care-seeking behaviour,T4,"The sudden appearance of unlinked cases of mpox in South Africa without a history of international travel, the high HIV prevalence among confirmed cases, and the high case fatality ratio suggest that (E1) community transmission (E1) is underway, and the cases detected to date represent a small proportion of all mpox cases that might be occurring in the community; it is unknown how long the virus may have been circulating. This may in part be due to the (C1) lack of early clinical recognition of an infection (C1) with which South Africa previously gained little experience during the ongoing global outbreak, potential (C1) pauci-symptomatic manifestation of the disease (C1), or (C1, E2) delays in care-seeking behaviour (C1, E2) due to (C2) limited access to care (C2) or (C2) fear of stigma (C2). At present, most of the transmission in the initial cases is linked to (C3) recent sexual contacts among men (C3), similar to the spread in newly affected countries during the 2022-2024 multi-country outbreak. For most confirmed cases, no epidemiological link has been established, possibly due in part to (C4) incomplete contact identification (C4).",social factors,healthcare delays
2024-DON525,recent sexual contacts among men,community transmission,T1,"The sudden appearance of unlinked cases of mpox in South Africa without a history of international travel, the high HIV prevalence among confirmed cases, and the high case fatality ratio suggest that (E1) community transmission (E1) is underway, and the cases detected to date represent a small proportion of all mpox cases that might be occurring in the community; it is unknown how long the virus may have been circulating. This may in part be due to the (C1) lack of early clinical recognition of an infection (C1) with which South Africa previously gained little experience during the ongoing global outbreak, potential (C1) pauci-symptomatic manifestation of the disease (C1), or (C1, E2) delays in care-seeking behaviour (C1, E2) due to (C2) limited access to care (C2) or (C2) fear of stigma (C2). At present, most of the transmission in the initial cases is linked to (C3) recent sexual contacts among men (C3), similar to the spread in newly affected countries during the 2022-2024 multi-country outbreak. For most confirmed cases, no epidemiological link has been established, possibly due in part to (C4) incomplete contact identification (C4).",behavioral factors,disease spread
2024-DON525,incomplete contact identification,community transmission,T1,"The sudden appearance of unlinked cases of mpox in South Africa without a history of international travel, the high HIV prevalence among confirmed cases, and the high case fatality ratio suggest that (E1) community transmission (E1) is underway, and the cases detected to date represent a small proportion of all mpox cases that might be occurring in the community; it is unknown how long the virus may have been circulating. This may in part be due to the (C1) lack of early clinical recognition of an infection (C1) with which South Africa previously gained little experience during the ongoing global outbreak, potential (C1) pauci-symptomatic manifestation of the disease (C1), or (C1, E2) delays in care-seeking behaviour (C1, E2) due to (C2) limited access to care (C2) or (C2) fear of stigma (C2). At present, most of the transmission in the initial cases is linked to (C3) recent sexual contacts among men (C3), similar to the spread in newly affected countries during the 2022-2024 multi-country outbreak. For most confirmed cases, no epidemiological link has been established, possibly due in part to (C4) incomplete contact identification (C4).",contact tracing,disease spread
2024-DON525,surveillance is strengthened,undetected community transmission,T1,"This suggests that (E1) undetected community transmission (E1) is occurring and that further cases can be expected as (C1) surveillance is strengthened (C1). The current risk to human health for the general public remains low in the country. The risk for gay men, bisexual men, other men who have sex with men, trans and gender diverse people, and sex workers is moderate, as currently assessed for the global outbreak.",disease monitoring,silent spread
2024-DON525,exposure through sexual contact,severe disease,T3,"The higher risk assessment is consistent with ongoing transmission among recognized risk groups due mainly to (C1) exposure through sexual contact (C1), and the (C2) higher prevalence of undetected or uncontrolled HIV infection in the country (C2) which also puts people at risk of (E1) severe disease (E1). There is potential for increased health impact should wider dissemination continue in vulnerable groups in South Africa or neighbouring countries. Data from ongoing mpox outbreaks show that the risk of (E1) severe disease (E1) and (E2) death (E2) is higher among (C3) children (C3), (C3) immunocompromised individuals including persons with poorly controlled HIV (C3), and (C3) pregnant women (C3). The most recent Joint United Nations Programme on HIV/AIDS (UNAIDS) data estimate HIV prevalence among men who have sex with men in South Africa to be around 30%, only 44% of whom are on antiretroviral therapy.",contact transmission,disease severity
2024-DON525,higher prevalence of undetected or uncontrolled HIV infection,severe disease,T3,"The higher risk assessment is consistent with ongoing transmission among recognized risk groups due mainly to (C1) exposure through sexual contact (C1), and the (C2) higher prevalence of undetected or uncontrolled HIV infection in the country (C2) which also puts people at risk of (E1) severe disease (E1). There is potential for increased health impact should wider dissemination continue in vulnerable groups in South Africa or neighbouring countries. Data from ongoing mpox outbreaks show that the risk of (E1) severe disease (E1) and (E2) death (E2) is higher among (C3) children (C3), (C3) immunocompromised individuals including persons with poorly controlled HIV (C3), and (C3) pregnant women (C3). The most recent Joint United Nations Programme on HIV/AIDS (UNAIDS) data estimate HIV prevalence among men who have sex with men in South Africa to be around 30%, only 44% of whom are on antiretroviral therapy.",disease management,disease severity
2024-DON525,"children, immunocompromised individuals including persons with poorly controlled HIV, and pregnant women",severe disease,T3,"The higher risk assessment is consistent with ongoing transmission among recognized risk groups due mainly to (C1) exposure through sexual contact (C1), and the (C2) higher prevalence of undetected or uncontrolled HIV infection in the country (C2) which also puts people at risk of (E1) severe disease (E1). There is potential for increased health impact should wider dissemination continue in vulnerable groups in South Africa or neighbouring countries. Data from ongoing mpox outbreaks show that the risk of (E1) severe disease (E1) and (E2) death (E2) is higher among (C3) children (C3), (C3) immunocompromised individuals including persons with poorly controlled HIV (C3), and (C3) pregnant women (C3). The most recent Joint United Nations Programme on HIV/AIDS (UNAIDS) data estimate HIV prevalence among men who have sex with men in South Africa to be around 30%, only 44% of whom are on antiretroviral therapy.",vulnerable populations,disease severity
2024-DON525,"children, immunocompromised individuals including persons with poorly controlled HIV, and pregnant women",death,T3,"The higher risk assessment is consistent with ongoing transmission among recognized risk groups due mainly to (C1) exposure through sexual contact (C1), and the (C2) higher prevalence of undetected or uncontrolled HIV infection in the country (C2) which also puts people at risk of (E1) severe disease (E1). There is potential for increased health impact should wider dissemination continue in vulnerable groups in South Africa or neighbouring countries. Data from ongoing mpox outbreaks show that the risk of (E1) severe disease (E1) and (E2) death (E2) is higher among (C3) children (C3), (C3) immunocompromised individuals including persons with poorly controlled HIV (C3), and (C3) pregnant women (C3). The most recent Joint United Nations Programme on HIV/AIDS (UNAIDS) data estimate HIV prevalence among men who have sex with men in South Africa to be around 30%, only 44% of whom are on antiretroviral therapy.",vulnerable populations,mortality rates
2024-DON525,hazard to health workers,severe mpox disease and death,T1,This makes this group extremely vulnerable to (E1) severe mpox disease and death (E1). There is also a (C1) hazard to health workers (C1) if they are not appropriately using (C2) personal protective equipment (PPE) (C2) when caring for patients with mpox.,occupational risk,disease severity
2024-DON525,not appropriately using personal protective equipment (PPE),severe mpox disease and death,T1,This makes this group extremely vulnerable to (E1) severe mpox disease and death (E1). There is also a (C1) hazard to health workers (C1) if they are not appropriately using (C2) personal protective equipment (PPE) (C2) when caring for patients with mpox.,safety failure,disease severity
2024-DON525,persons who are immunocompromised with uncontrolled HIV and other co-morbidities,undetected and unreported cases,T1,"In contrast, the CFR among cases reported in South Africa in 2024 is extremely high (15%), as most detected cases are among (C1) persons who are immunocompromised with uncontrolled HIV and other co-morbidities (C1). (C2) Persons with less severe mpox (C2) are less likely to recognize the condition or seek diagnosis and care; therefore, such cases may remain (E1) undetected and unreported (E1). Vaccination with mpox vaccines has been shown to be effective against mpox. The last case of smallpox in South Africa was reported in 1972, and smallpox vaccination stopped shortly after the global eradication of the disease in 1980.",vulnerable populations,hidden cases
2024-DON525,persons with less severe mpox,undetected and unreported cases,T1,"In contrast, the CFR among cases reported in South Africa in 2024 is extremely high (15%), as most detected cases are among (C1) persons who are immunocompromised with uncontrolled HIV and other co-morbidities (C1). (C2) Persons with less severe mpox (C2) are less likely to recognize the condition or seek diagnosis and care; therefore, such cases may remain (E1) undetected and unreported (E1). Vaccination with mpox vaccines has been shown to be effective against mpox. The last case of smallpox in South Africa was reported in 1972, and smallpox vaccination stopped shortly after the global eradication of the disease in 1980.",disease severity,hidden cases
2024-DON525,limited awareness of mpox and lack of knowledge about practices for prevention among health workers and among key populations,risk for mpox,T1,"Thus, any immunity from prior smallpox vaccination (which is cross-protective for mpox) will at best now only be present in some persons over the age of 44 years. The median age of mpox cases in the current global outbreak is 34 years (IQR: 29 - 41) and within South Africa, reported cases are aged between 17-43 years. The (C1) limited awareness of mpox and lack of knowledge about practices for prevention among health workers and among key populations such as sex workers or men who have sex with men in the country (C1) exacerbates their (E1) risk for mpox (E1). Anyone suffering from disfiguring skin conditions, including mpox, may experience fear and stigma, which can be further compounded for key populations. There is concern that the mpox outbreak in South Africa will continue to evolve given: The (C2) high likelihood of under-detection and under-reporting of local transmission (C2), given that reported cases have to date almost exclusively affected the most vulnerable. Currently, all detected cases have presented with (C3) severe disease and extensive skin lesions (C3), which could lead to more (E2) viral transmission (E2) and risks poor outcomes for the patients. While the government and partners are mobilized to introduce treatment for affected patients and vaccines for people at risk, these countermeasures are not yet widely available in the country. Public awareness of mpox and information about modes of transmission or possible amplifying events or risk of exposure in sex-on-premises venues remains limited in South Africa.",education gaps,disease risk
2024-DON525,high likelihood of under-detection and under-reporting of local transmission,viral transmission,T1,"Thus, any immunity from prior smallpox vaccination (which is cross-protective for mpox) will at best now only be present in some persons over the age of 44 years. The median age of mpox cases in the current global outbreak is 34 years (IQR: 29 - 41) and within South Africa, reported cases are aged between 17-43 years. The (C1) limited awareness of mpox and lack of knowledge about practices for prevention among health workers and among key populations such as sex workers or men who have sex with men in the country (C1) exacerbates their (E1) risk for mpox (E1). Anyone suffering from disfiguring skin conditions, including mpox, may experience fear and stigma, which can be further compounded for key populations. There is concern that the mpox outbreak in South Africa will continue to evolve given: The (C2) high likelihood of under-detection and under-reporting of local transmission (C2), given that reported cases have to date almost exclusively affected the most vulnerable. Currently, all detected cases have presented with (C3) severe disease and extensive skin lesions (C3), which could lead to more (E2) viral transmission (E2) and risks poor outcomes for the patients. While the government and partners are mobilized to introduce treatment for affected patients and vaccines for people at risk, these countermeasures are not yet widely available in the country. Public awareness of mpox and information about modes of transmission or possible amplifying events or risk of exposure in sex-on-premises venues remains limited in South Africa.",detection challenges,disease transmission
2024-DON525,severe disease and extensive skin lesions,viral transmission,T3,"Thus, any immunity from prior smallpox vaccination (which is cross-protective for mpox) will at best now only be present in some persons over the age of 44 years. The median age of mpox cases in the current global outbreak is 34 years (IQR: 29 - 41) and within South Africa, reported cases are aged between 17-43 years. The (C1) limited awareness of mpox and lack of knowledge about practices for prevention among health workers and among key populations such as sex workers or men who have sex with men in the country (C1) exacerbates their (E1) risk for mpox (E1). Anyone suffering from disfiguring skin conditions, including mpox, may experience fear and stigma, which can be further compounded for key populations. There is concern that the mpox outbreak in South Africa will continue to evolve given: The (C2) high likelihood of under-detection and under-reporting of local transmission (C2), given that reported cases have to date almost exclusively affected the most vulnerable. Currently, all detected cases have presented with (C3) severe disease and extensive skin lesions (C3), which could lead to more (E2) viral transmission (E2) and risks poor outcomes for the patients. While the government and partners are mobilized to introduce treatment for affected patients and vaccines for people at risk, these countermeasures are not yet widely available in the country. Public awareness of mpox and information about modes of transmission or possible amplifying events or risk of exposure in sex-on-premises venues remains limited in South Africa.",disease symptoms,disease transmission
2024-DON525,outbreaks of mpox,risk of further transmission,T1,"Concurrent (C1) outbreaks of mpox (C1) are occurring in Africa and elsewhere, increasing the (E1) risk of further transmission (E1).",disease outbreaks,disease spread
2024-DON522,Infants and children under five years of age are at highest risk of severe disease and death,number of cases reported weekly remains consistently high,T1,"In the Democratic Republic of the Congo, most reported cases in known endemic provinces continue to be among children under 15 years of age, especially in young children. (C1) Infants and children under five years of age are at highest risk of severe disease and death (C1), particularly where (C2) prompt optimal case management is limited or unavailable (C2). The (E1) number of cases reported weekly remains consistently high (E1) while the (E1) outbreak continues to expand geographically (E1).",age vulnerability,case frequency
2024-DON522,prompt optimal case management is limited or unavailable,number of cases reported weekly remains consistently high,T1,"In the Democratic Republic of the Congo, most reported cases in known endemic provinces continue to be among children under 15 years of age, especially in young children. (C1) Infants and children under five years of age are at highest risk of severe disease and death (C1), particularly where (C2) prompt optimal case management is limited or unavailable (C2). The (E1) number of cases reported weekly remains consistently high (E1) while the (E1) outbreak continues to expand geographically (E1).",healthcare availability,case frequency
2024-DON522,human-to-human contact (sexual and non-sexual),mpox transmission,T1,"High test positivity among tested cases in most provinces also suggests that (E1) undetected transmission (E1) is likely ongoing in the community. Transmission of mpox due to clade I MPXV via sexual contact in key populations was first identified in the Democratic Republic of the Congo in 2023. In South Kivu province, (E2) mpox transmission (E2) is sustained through (C1) human-to-human contact (sexual and non-sexual) (C1). The global outbreak 2022 — 2024 has shown that (C2) sexual contact (C2) enables (E3) faster and more efficient spread of the virus (E3) from one person to another due to (C3) direct contact of mucous membranes between people (C3), (C3) contact with multiple partners (C3), a possibly (C3) shorter incubation period on average (C3), and a (C3) longer infectious period for immunocompromised individuals (C3). The newly documented occurrence of mpox in North Kivu is very concerning.",contact transmission,disease transmission
2024-DON522,sexual contact,faster and more efficient spread of the virus,T1,"High test positivity among tested cases in most provinces also suggests that (E1) undetected transmission (E1) is likely ongoing in the community. Transmission of mpox due to clade I MPXV via sexual contact in key populations was first identified in the Democratic Republic of the Congo in 2023. In South Kivu province, (E2) mpox transmission (E2) is sustained through (C1) human-to-human contact (sexual and non-sexual) (C1). The global outbreak 2022 — 2024 has shown that (C2) sexual contact (C2) enables (E3) faster and more efficient spread of the virus (E3) from one person to another due to (C3) direct contact of mucous membranes between people (C3), (C3) contact with multiple partners (C3), a possibly (C3) shorter incubation period on average (C3), and a (C3) longer infectious period for immunocompromised individuals (C3). The newly documented occurrence of mpox in North Kivu is very concerning.",contact transmission,virus transmission
2024-DON522,direct contact of mucous membranes between people,faster and more efficient spread of the virus,T3,"High test positivity among tested cases in most provinces also suggests that (E1) undetected transmission (E1) is likely ongoing in the community. Transmission of mpox due to clade I MPXV via sexual contact in key populations was first identified in the Democratic Republic of the Congo in 2023. In South Kivu province, (E2) mpox transmission (E2) is sustained through (C1) human-to-human contact (sexual and non-sexual) (C1). The global outbreak 2022 — 2024 has shown that (C2) sexual contact (C2) enables (E3) faster and more efficient spread of the virus (E3) from one person to another due to (C3) direct contact of mucous membranes between people (C3), (C3) contact with multiple partners (C3), a possibly (C3) shorter incubation period on average (C3), and a (C3) longer infectious period for immunocompromised individuals (C3). The newly documented occurrence of mpox in North Kivu is very concerning.",contact transmission,virus transmission
2024-DON522,contact with multiple partners,faster and more efficient spread of the virus,T3,"High test positivity among tested cases in most provinces also suggests that (E1) undetected transmission (E1) is likely ongoing in the community. Transmission of mpox due to clade I MPXV via sexual contact in key populations was first identified in the Democratic Republic of the Congo in 2023. In South Kivu province, (E2) mpox transmission (E2) is sustained through (C1) human-to-human contact (sexual and non-sexual) (C1). The global outbreak 2022 — 2024 has shown that (C2) sexual contact (C2) enables (E3) faster and more efficient spread of the virus (E3) from one person to another due to (C3) direct contact of mucous membranes between people (C3), (C3) contact with multiple partners (C3), a possibly (C3) shorter incubation period on average (C3), and a (C3) longer infectious period for immunocompromised individuals (C3). The newly documented occurrence of mpox in North Kivu is very concerning.",behavioral risks,virus transmission
2024-DON522,shorter incubation period on average,faster and more efficient spread of the virus,T3,"High test positivity among tested cases in most provinces also suggests that (E1) undetected transmission (E1) is likely ongoing in the community. Transmission of mpox due to clade I MPXV via sexual contact in key populations was first identified in the Democratic Republic of the Congo in 2023. In South Kivu province, (E2) mpox transmission (E2) is sustained through (C1) human-to-human contact (sexual and non-sexual) (C1). The global outbreak 2022 — 2024 has shown that (C2) sexual contact (C2) enables (E3) faster and more efficient spread of the virus (E3) from one person to another due to (C3) direct contact of mucous membranes between people (C3), (C3) contact with multiple partners (C3), a possibly (C3) shorter incubation period on average (C3), and a (C3) longer infectious period for immunocompromised individuals (C3). The newly documented occurrence of mpox in North Kivu is very concerning.",disease progression,virus transmission
2024-DON522,longer infectious period for immunocompromised individuals,faster and more efficient spread of the virus,T3,"High test positivity among tested cases in most provinces also suggests that (E1) undetected transmission (E1) is likely ongoing in the community. Transmission of mpox due to clade I MPXV via sexual contact in key populations was first identified in the Democratic Republic of the Congo in 2023. In South Kivu province, (E2) mpox transmission (E2) is sustained through (C1) human-to-human contact (sexual and non-sexual) (C1). The global outbreak 2022 — 2024 has shown that (C2) sexual contact (C2) enables (E3) faster and more efficient spread of the virus (E3) from one person to another due to (C3) direct contact of mucous membranes between people (C3), (C3) contact with multiple partners (C3), a possibly (C3) shorter incubation period on average (C3), and a (C3) longer infectious period for immunocompromised individuals (C3). The newly documented occurrence of mpox in North Kivu is very concerning.",disease duration,virus transmission
2024-DON522,immune suppression,severe disease and death among persons with mpox,T1,"The additional public health impact of sustained human-to-human sexual transmission of mpox in the country indicates that a vigorous response is required. One of the main risk factors for (E1) severe disease and death among persons with mpox (E1) is (C1) immune suppression (C1), especially among those with advanced HIV infection. The prevalence of HIV in the general adult population in the Democratic Republic of the Congo is estimated to be approximately 1%, higher in the eastern provinces than elsewhere, and higher in key populations including estimates of a prevalence of 7.5% among sex workers and 7.1% among men who have sex with men. The (C2) higher HIV prevalence and the challenge in accessing antiretroviral treatment (C2) puts these groups at higher risk for (E2) severe mpox and death (E2) if they get infected.",immune deficiency,disease severity
2024-DON522,higher HIV prevalence and the challenge in accessing antiretroviral treatment,severe mpox and death,T1,"The additional public health impact of sustained human-to-human sexual transmission of mpox in the country indicates that a vigorous response is required. One of the main risk factors for (E1) severe disease and death among persons with mpox (E1) is (C1) immune suppression (C1), especially among those with advanced HIV infection. The prevalence of HIV in the general adult population in the Democratic Republic of the Congo is estimated to be approximately 1%, higher in the eastern provinces than elsewhere, and higher in key populations including estimates of a prevalence of 7.5% among sex workers and 7.1% among men who have sex with men. The (C2) higher HIV prevalence and the challenge in accessing antiretroviral treatment (C2) puts these groups at higher risk for (E2) severe mpox and death (E2) if they get infected.",disease management,disease severity
2024-DON522,lack of timely access to diagnostics in many areas,rapid response,T3,"The occurrence of cases among a broad range of occupational groups and within households also suggests that (E1) the outbreak in South Kivu is already spreading into the wider community (E1). Understanding of the dynamics of MPXV transmission in the Democratic Republic of the Congo is improving with the emergency measures being put in place. Nonetheless, (C1) a lack of timely access to diagnostics in many areas (C1), (C1) incomplete epidemiological investigations (C1), (C1) challenges in contact tracing (C1), and (C1) extensive but inconclusive animal investigations (C1) continue to hamper (E2) rapid response (E2). While (C2) zoonotic spill over events (C2) are considered to still represent a major source of exposure in the country, the (C2) animal reservoir remains unknown (C2).",diagnostic delays,emergency preparedness
2024-DON522,incomplete epidemiological investigations,rapid response,T3,"The occurrence of cases among a broad range of occupational groups and within households also suggests that (E1) the outbreak in South Kivu is already spreading into the wider community (E1). Understanding of the dynamics of MPXV transmission in the Democratic Republic of the Congo is improving with the emergency measures being put in place. Nonetheless, (C1) a lack of timely access to diagnostics in many areas (C1), (C1) incomplete epidemiological investigations (C1), (C1) challenges in contact tracing (C1), and (C1) extensive but inconclusive animal investigations (C1) continue to hamper (E2) rapid response (E2). While (C2) zoonotic spill over events (C2) are considered to still represent a major source of exposure in the country, the (C2) animal reservoir remains unknown (C2).",research gaps,emergency preparedness
2024-DON522,challenges in contact tracing,rapid response,T3,"The occurrence of cases among a broad range of occupational groups and within households also suggests that (E1) the outbreak in South Kivu is already spreading into the wider community (E1). Understanding of the dynamics of MPXV transmission in the Democratic Republic of the Congo is improving with the emergency measures being put in place. Nonetheless, (C1) a lack of timely access to diagnostics in many areas (C1), (C1) incomplete epidemiological investigations (C1), (C1) challenges in contact tracing (C1), and (C1) extensive but inconclusive animal investigations (C1) continue to hamper (E2) rapid response (E2). While (C2) zoonotic spill over events (C2) are considered to still represent a major source of exposure in the country, the (C2) animal reservoir remains unknown (C2).",disease tracking,emergency preparedness
2024-DON522,extensive but inconclusive animal investigations,rapid response,T3,"The occurrence of cases among a broad range of occupational groups and within households also suggests that (E1) the outbreak in South Kivu is already spreading into the wider community (E1). Understanding of the dynamics of MPXV transmission in the Democratic Republic of the Congo is improving with the emergency measures being put in place. Nonetheless, (C1) a lack of timely access to diagnostics in many areas (C1), (C1) incomplete epidemiological investigations (C1), (C1) challenges in contact tracing (C1), and (C1) extensive but inconclusive animal investigations (C1) continue to hamper (E2) rapid response (E2). While (C2) zoonotic spill over events (C2) are considered to still represent a major source of exposure in the country, the (C2) animal reservoir remains unknown (C2).",animal research,emergency preparedness
2024-DON522,zoonotic spill over events,the outbreak in South Kivu is already spreading into the wider community,T1,"The occurrence of cases among a broad range of occupational groups and within households also suggests that (E1) the outbreak in South Kivu is already spreading into the wider community (E1). Understanding of the dynamics of MPXV transmission in the Democratic Republic of the Congo is improving with the emergency measures being put in place. Nonetheless, (C1) a lack of timely access to diagnostics in many areas (C1), (C1) incomplete epidemiological investigations (C1), (C1) challenges in contact tracing (C1), and (C1) extensive but inconclusive animal investigations (C1) continue to hamper (E2) rapid response (E2). While (C2) zoonotic spill over events (C2) are considered to still represent a major source of exposure in the country, the (C2) animal reservoir remains unknown (C2).",animal transmission,community spread
2024-DON522,human-to-human transmission,rapid expansion of the outbreak,T1,"The new features of (C1) human-to-human transmission (C1) observed in South Kivu and North Kivu raise additional concern about a further (E1) rapid expansion of the outbreak (E1) in the eastern mining provinces, as well as the rest of the country and other countries which share national borders. From 1 January to 26 May 2024, 7 851 suspected cases were reported, compared to 3 924 suspected cases reported during the same period in 2023. The (E2) geographic expansion to new areas (E2), such as Kinshasa and North Kivu, continues in 2024. Only 3 of 26 provinces have not yet reported mpox in 2024.",disease transmission,outbreak spread
2024-DON522,human-to-human transmission,geographic expansion to new areas,T1,"The new features of (C1) human-to-human transmission (C1) observed in South Kivu and North Kivu raise additional concern about a further (E1) rapid expansion of the outbreak (E1) in the eastern mining provinces, as well as the rest of the country and other countries which share national borders. From 1 January to 26 May 2024, 7 851 suspected cases were reported, compared to 3 924 suspected cases reported during the same period in 2023. The (E2) geographic expansion to new areas (E2), such as Kinshasa and North Kivu, continues in 2024. Only 3 of 26 provinces have not yet reported mpox in 2024.",disease transmission,spatial spread
2024-DON522,MPXV continues to move into the immunity gap left following eradication of smallpox,secondary or sustained human-to-human transmission,T1,"While some cases in the newly affected provinces are linked to travel from endemic areas, others represent (E1) secondary or sustained human-to-human transmission (E1), and the source of infection for several of them remains unknown. The current situation remains extremely concerning as (C1) MPXV continues to move into the immunity gap left following eradication of smallpox (C1). Surveillance and investigating alerts are limited by (C2) logistical and resource challenges (C2), and (C2) laboratory capacities are limited to two national laboratories (C2), one in Kinshasa and one in Goma so only (E2) 18% of reported cases in 2024 have been tested by PCR (E2). Testing through GeneXpert has begun in Equateur and South Kivu province, and validation of the findings is ongoing.",virus spread,disease spread
2024-DON522,"logistical and resource challenges, laboratory capacities are limited to two national laboratories",18% of reported cases in 2024 have been tested by PCR,T3,"While some cases in the newly affected provinces are linked to travel from endemic areas, others represent (E1) secondary or sustained human-to-human transmission (E1), and the source of infection for several of them remains unknown. The current situation remains extremely concerning as (C1) MPXV continues to move into the immunity gap left following eradication of smallpox (C1). Surveillance and investigating alerts are limited by (C2) logistical and resource challenges (C2), and (C2) laboratory capacities are limited to two national laboratories (C2), one in Kinshasa and one in Goma so only (E2) 18% of reported cases in 2024 have been tested by PCR (E2). Testing through GeneXpert has begun in Equateur and South Kivu province, and validation of the findings is ongoing.",resource limitations,disease testing
2024-DON522,support of WHO and other partners,response capacities to mpox in the country,T1,Response capacities to mpox in the country rely to a great extent on the (C1) support of WHO and other partners (C1). Immunogenicity and safety studies of MVA-BN vaccine have been ongoing in the Democratic Republic of the Congo since 2016. The national immunization technical advisory group (GTCV) released recommendations on the use of mpox vaccines in the country for persons at risk. These included recommendations for preferred use of LC16 in children and use of MVA-BN in adults.,healthcare support,healthcare response
2024-DON522,,,No causality,"The Ministry of Public Health, Hygiene and Prevention (MSPHP) has announced its intention to vaccinate persons at risk through use of LC16 and MVA-BN vaccinia-based mpox vaccines and asked the national regulatory authority (ACOREP) to authorize temporary use of these vaccines. This regulatory review is underway. Further clinical efficacy and safety studies are being planned for LC16 in the country.",No context,No context
2024-DON522,consumption of bushmeat,community outbreaks,T1,"The Expanded Programme on Immunization (EPI) is developing emergency response immunization strategies for persons and areas at risk through extensive consultation internally, with WHO and with partners. The antiviral medication tecovirimat is undergoing clinical efficacy studies in two study sites in the Democratic Republic of the Congo: Kole in Sankuru Province and Tunde in Maniema Province. This study is expected to complete recruitment in 2024. Access to tecovirimat is possible through request from WHO for compassionate use or through application for use under the WHO MEURI protocol. Risk communication and community engagement are of critical importance for modes of transmission historically reported as community outbreaks including from (C1) consumption of bushmeat (C1), as well as for the newly described (C2) risk of sexual transmission (C2), particularly among (C3) sex workers and other key populations (C3).",dietary habits,disease spread
2024-DON522,risk of sexual transmission,community outbreaks,T1,"The Expanded Programme on Immunization (EPI) is developing emergency response immunization strategies for persons and areas at risk through extensive consultation internally, with WHO and with partners. The antiviral medication tecovirimat is undergoing clinical efficacy studies in two study sites in the Democratic Republic of the Congo: Kole in Sankuru Province and Tunde in Maniema Province. This study is expected to complete recruitment in 2024. Access to tecovirimat is possible through request from WHO for compassionate use or through application for use under the WHO MEURI protocol. Risk communication and community engagement are of critical importance for modes of transmission historically reported as community outbreaks including from (C1) consumption of bushmeat (C1), as well as for the newly described (C2) risk of sexual transmission (C2), particularly among (C3) sex workers and other key populations (C3).",disease transmission,disease spread
2024-DON522,sex workers and other key populations,community outbreaks,T1,"The Expanded Programme on Immunization (EPI) is developing emergency response immunization strategies for persons and areas at risk through extensive consultation internally, with WHO and with partners. The antiviral medication tecovirimat is undergoing clinical efficacy studies in two study sites in the Democratic Republic of the Congo: Kole in Sankuru Province and Tunde in Maniema Province. This study is expected to complete recruitment in 2024. Access to tecovirimat is possible through request from WHO for compassionate use or through application for use under the WHO MEURI protocol. Risk communication and community engagement are of critical importance for modes of transmission historically reported as community outbreaks including from (C1) consumption of bushmeat (C1), as well as for the newly described (C2) risk of sexual transmission (C2), particularly among (C3) sex workers and other key populations (C3).",population risk,disease spread
2024-DON522,lack of effective dissemination to date of health messages for key populations,further risk,T1,"According to a study conducted by USAID and Breakthrough Action in 2022, awareness of the risks associated with mpox among the general population in the Democratic Republic of the Congo was low, despite the disease being reported in remote endemic areas since 1970. The (C1) lack of effective dissemination to date of health messages for key populations such as sex workers or men who have sex with men in the country (C1) exposes them to (E1) further risk (E1). Anyone suffering from disfiguring skin conditions, including mpox, may suffer from (C2) fear and stigma (C2), which can be further compounded for persons at risk of acquiring the disease through sexual contact. The continued development of the mpox outbreak in the Democratic Republic of the Congo remains concerning due to: The continuing (C3) high incidence of cases reported in 2024 compared to previous years (C3), with two thirds of reported cases and more than four fifths of deaths occurring primarily among children in known endemic areas. Transmission through (C4) sexual contact of clade I MPXV among key populations and other groups with multiple partners and high mobility in densely populated mining areas (C4) has led to (E2) sustained community transmission in South Kivu (E2). The outbreak characterized by sexual contact transmission has revealed a (C5) new strain of MPXV with genetic mutations (C5) suggestive of (E3) extended human-to-human transmission and geographic expansion (E3).",communication failure,risk factors
2024-DON522,fear and stigma,further risk,T1,"According to a study conducted by USAID and Breakthrough Action in 2022, awareness of the risks associated with mpox among the general population in the Democratic Republic of the Congo was low, despite the disease being reported in remote endemic areas since 1970. The (C1) lack of effective dissemination to date of health messages for key populations such as sex workers or men who have sex with men in the country (C1) exposes them to (E1) further risk (E1). Anyone suffering from disfiguring skin conditions, including mpox, may suffer from (C2) fear and stigma (C2), which can be further compounded for persons at risk of acquiring the disease through sexual contact. The continued development of the mpox outbreak in the Democratic Republic of the Congo remains concerning due to: The continuing (C3) high incidence of cases reported in 2024 compared to previous years (C3), with two thirds of reported cases and more than four fifths of deaths occurring primarily among children in known endemic areas. Transmission through (C4) sexual contact of clade I MPXV among key populations and other groups with multiple partners and high mobility in densely populated mining areas (C4) has led to (E2) sustained community transmission in South Kivu (E2). The outbreak characterized by sexual contact transmission has revealed a (C5) new strain of MPXV with genetic mutations (C5) suggestive of (E3) extended human-to-human transmission and geographic expansion (E3).",social factors,risk factors
2024-DON522,high incidence of cases reported in 2024 compared to previous years,further risk,T1,"According to a study conducted by USAID and Breakthrough Action in 2022, awareness of the risks associated with mpox among the general population in the Democratic Republic of the Congo was low, despite the disease being reported in remote endemic areas since 1970. The (C1) lack of effective dissemination to date of health messages for key populations such as sex workers or men who have sex with men in the country (C1) exposes them to (E1) further risk (E1). Anyone suffering from disfiguring skin conditions, including mpox, may suffer from (C2) fear and stigma (C2), which can be further compounded for persons at risk of acquiring the disease through sexual contact. The continued development of the mpox outbreak in the Democratic Republic of the Congo remains concerning due to: The continuing (C3) high incidence of cases reported in 2024 compared to previous years (C3), with two thirds of reported cases and more than four fifths of deaths occurring primarily among children in known endemic areas. Transmission through (C4) sexual contact of clade I MPXV among key populations and other groups with multiple partners and high mobility in densely populated mining areas (C4) has led to (E2) sustained community transmission in South Kivu (E2). The outbreak characterized by sexual contact transmission has revealed a (C5) new strain of MPXV with genetic mutations (C5) suggestive of (E3) extended human-to-human transmission and geographic expansion (E3).",disease trends,risk factors
2024-DON522,sexual contact of clade I MPXV among key populations and other groups with multiple partners and high mobility in densely populated mining areas,sustained community transmission in South Kivu,T1,"According to a study conducted by USAID and Breakthrough Action in 2022, awareness of the risks associated with mpox among the general population in the Democratic Republic of the Congo was low, despite the disease being reported in remote endemic areas since 1970. The (C1) lack of effective dissemination to date of health messages for key populations such as sex workers or men who have sex with men in the country (C1) exposes them to (E1) further risk (E1). Anyone suffering from disfiguring skin conditions, including mpox, may suffer from (C2) fear and stigma (C2), which can be further compounded for persons at risk of acquiring the disease through sexual contact. The continued development of the mpox outbreak in the Democratic Republic of the Congo remains concerning due to: The continuing (C3) high incidence of cases reported in 2024 compared to previous years (C3), with two thirds of reported cases and more than four fifths of deaths occurring primarily among children in known endemic areas. Transmission through (C4) sexual contact of clade I MPXV among key populations and other groups with multiple partners and high mobility in densely populated mining areas (C4) has led to (E2) sustained community transmission in South Kivu (E2). The outbreak characterized by sexual contact transmission has revealed a (C5) new strain of MPXV with genetic mutations (C5) suggestive of (E3) extended human-to-human transmission and geographic expansion (E3).",behavioral factors,disease spread
2024-DON522,new strain of MPXV with genetic mutations,extended human-to-human transmission and geographic expansion,T1,"According to a study conducted by USAID and Breakthrough Action in 2022, awareness of the risks associated with mpox among the general population in the Democratic Republic of the Congo was low, despite the disease being reported in remote endemic areas since 1970. The (C1) lack of effective dissemination to date of health messages for key populations such as sex workers or men who have sex with men in the country (C1) exposes them to (E1) further risk (E1). Anyone suffering from disfiguring skin conditions, including mpox, may suffer from (C2) fear and stigma (C2), which can be further compounded for persons at risk of acquiring the disease through sexual contact. The continued development of the mpox outbreak in the Democratic Republic of the Congo remains concerning due to: The continuing (C3) high incidence of cases reported in 2024 compared to previous years (C3), with two thirds of reported cases and more than four fifths of deaths occurring primarily among children in known endemic areas. Transmission through (C4) sexual contact of clade I MPXV among key populations and other groups with multiple partners and high mobility in densely populated mining areas (C4) has led to (E2) sustained community transmission in South Kivu (E2). The outbreak characterized by sexual contact transmission has revealed a (C5) new strain of MPXV with genetic mutations (C5) suggestive of (E3) extended human-to-human transmission and geographic expansion (E3).",viral evolution,disease spread
2024-DON522,co-infections with HIV and other sexually transmitted infections,outbreaks in the city,T3,"This new MPXV strain is affecting newly reported areas in southern and eastern provinces. While it is not known whether this variant is inherently more transmissible or leads to more severe diseases than other virus strains circulating in the country, (C1) co-infections with HIV and other sexually transmitted infections (C1) are being documented. In 2023 and 2024, mpox cases have occurred in ​​Kinshasa associated with (C2) river boat travel (C2) and leading to (E1) outbreaks in the city (E1). At the time of reporting, new cases in the Nsele health zone in Kinshasa have been confirmed. There is (E2) high (around 70% overall) or very high (around 90% in South Kivu) test positivity among reported cases (E2), despite efforts to significantly expand surveillance.",disease interactions,urban outbreaks
2024-DON522,river boat travel,outbreaks in the city,T3,"This new MPXV strain is affecting newly reported areas in southern and eastern provinces. While it is not known whether this variant is inherently more transmissible or leads to more severe diseases than other virus strains circulating in the country, (C1) co-infections with HIV and other sexually transmitted infections (C1) are being documented. In 2023 and 2024, mpox cases have occurred in ​​Kinshasa associated with (C2) river boat travel (C2) and leading to (E1) outbreaks in the city (E1). At the time of reporting, new cases in the Nsele health zone in Kinshasa have been confirmed. There is (E2) high (around 70% overall) or very high (around 90% in South Kivu) test positivity among reported cases (E2), despite efforts to significantly expand surveillance.",transportation risks,urban outbreaks
2024-DON522,resource mobilization is slow,extensive undetected circulation of the virus,T3,"This suggests significant under detection or underreporting of transmission. While the government has activated an emergency response across the country with support from in-country and global partners, resources to respond over such a wide geographic area remain insufficient, and (C1) resource mobilization is slow (C1). Public awareness remains limited, resources are scarce, and (C2) technical as well as financial support is needed (C2) to ensure a robust response at provincial/local, national, and international levels. A concurrent outbreak of mpox is occurring in the Republic of Congo, with cases genetically similar to the MPXV strain circulating in neighbouring endemic provinces of the Democratic Republic of the Congo provinces. A new outbreak of mpox due to clade IIb MPXV linked to the ongoing global outbreak is occurring among key populations in the Republic of South Africa, with to date only cases with severe disease and advanced HIV infection being reported, suggesting (E1) extensive undetected circulation of the virus (E1). (C3) Travel between South Africa and the Democratic Republic of the Congo linked to commercial activity between the two countries (C3) further puts populations at risk. In epidemiological week 16 to 18, an outbreak of 45 suspected cases of mpox were reported in two prison cells in Lodja Health Zone in Sankuru Province of the Democratic Republic of the Congo. Samples were collected and sent to the lab for confirmation and results are currently awaited.",funding challenges,silent spread
2024-DON522,technical as well as financial support is needed,extensive undetected circulation of the virus,T3,"This suggests significant under detection or underreporting of transmission. While the government has activated an emergency response across the country with support from in-country and global partners, resources to respond over such a wide geographic area remain insufficient, and (C1) resource mobilization is slow (C1). Public awareness remains limited, resources are scarce, and (C2) technical as well as financial support is needed (C2) to ensure a robust response at provincial/local, national, and international levels. A concurrent outbreak of mpox is occurring in the Republic of Congo, with cases genetically similar to the MPXV strain circulating in neighbouring endemic provinces of the Democratic Republic of the Congo provinces. A new outbreak of mpox due to clade IIb MPXV linked to the ongoing global outbreak is occurring among key populations in the Republic of South Africa, with to date only cases with severe disease and advanced HIV infection being reported, suggesting (E1) extensive undetected circulation of the virus (E1). (C3) Travel between South Africa and the Democratic Republic of the Congo linked to commercial activity between the two countries (C3) further puts populations at risk. In epidemiological week 16 to 18, an outbreak of 45 suspected cases of mpox were reported in two prison cells in Lodja Health Zone in Sankuru Province of the Democratic Republic of the Congo. Samples were collected and sent to the lab for confirmation and results are currently awaited.",support needs,silent spread
2024-DON522,Travel between South Africa and the Democratic Republic of the Congo linked to commercial activity,extensive undetected circulation of the virus,T3,"This suggests significant under detection or underreporting of transmission. While the government has activated an emergency response across the country with support from in-country and global partners, resources to respond over such a wide geographic area remain insufficient, and (C1) resource mobilization is slow (C1). Public awareness remains limited, resources are scarce, and (C2) technical as well as financial support is needed (C2) to ensure a robust response at provincial/local, national, and international levels. A concurrent outbreak of mpox is occurring in the Republic of Congo, with cases genetically similar to the MPXV strain circulating in neighbouring endemic provinces of the Democratic Republic of the Congo provinces. A new outbreak of mpox due to clade IIb MPXV linked to the ongoing global outbreak is occurring among key populations in the Republic of South Africa, with to date only cases with severe disease and advanced HIV infection being reported, suggesting (E1) extensive undetected circulation of the virus (E1). (C3) Travel between South Africa and the Democratic Republic of the Congo linked to commercial activity between the two countries (C3) further puts populations at risk. In epidemiological week 16 to 18, an outbreak of 45 suspected cases of mpox were reported in two prison cells in Lodja Health Zone in Sankuru Province of the Democratic Republic of the Congo. Samples were collected and sent to the lab for confirmation and results are currently awaited.",travel transmission,silent spread
2024-DON524,avian influenza viruses are circulating in poultry,risk for infection and small clusters of human cases,T1,"This new information does not change WHO’s risk assessment. This is the first laboratory-confirmed human case of infection with an influenza A(H5N2) virus reported globally, and the first A(H5) virus infection in a person reported in Mexico. The case had multiple underlying conditions, and although the source of exposure has not been definitively determined, genetic analysis by authorities in Mexico identified that the virus from the patient has a 99% similarity with the strain obtained during 2024 in birds in Texcoco State of Mexico. Whenever (C1) avian influenza viruses are circulating in poultry (C1), there is a (E1) risk for infection and small clusters of human cases (E1) due to (C2) exposure to infected poultry or contaminated environments (C2).",animal transmission,disease clusters
2024-DON524,exposure to infected poultry or contaminated environments,risk for infection and small clusters of human cases,T3,"This new information does not change WHO’s risk assessment. This is the first laboratory-confirmed human case of infection with an influenza A(H5N2) virus reported globally, and the first A(H5) virus infection in a person reported in Mexico. The case had multiple underlying conditions, and although the source of exposure has not been definitively determined, genetic analysis by authorities in Mexico identified that the virus from the patient has a 99% similarity with the strain obtained during 2024 in birds in Texcoco State of Mexico. Whenever (C1) avian influenza viruses are circulating in poultry (C1), there is a (E1) risk for infection and small clusters of human cases (E1) due to (C2) exposure to infected poultry or contaminated environments (C2).",animal exposure,disease clusters
2024-DON524,A(H5) viruses from previous events have not acquired the ability to sustain transmission between humans,risk of sustained human-to-human spread remains assessed as low,T1,"Epidemiological and virological evidence available so far suggests that (C1) A(H5) viruses from previous events have not acquired the ability to sustain transmission between humans (C1), thus the (E1) risk of sustained human-to-human spread remains assessed as low (E1).",virus transmission,transmission risk
2024-DON524,,,No causality,"There are no specific vaccines for preventing influenza A(H5) virus infection in humans. Candidate vaccines to prevent A(H5) infection in humans have been developed for pandemic preparedness purposes. Close analysis of the epidemiological situation, further characterization of the most recent viruses (in human and birds) and serological investigations are critical to assess associated risks and to adjust risk management measures in a timely manner. Based on the available information, WHO assesses the current risk to the general population posed by this virus to be low.",No context,No context
2024-DON524,A(H5N2) viruses detected in local animal populations,risk assessment will be reviewed,T1,"If needed, the risk assessment will be reviewed should further epidemiological or virological information, including information on (C1) A(H5N2) viruses detected in local animal populations (C1), become available.",virus detection,safety evaluation
2024-DON523,contact with infected poultry or contaminated environments,mild clinical illness,T1,"Most human cases of infection with avian influenza A(H9N2) viruses are exposed to the virus through (C1) contact with infected poultry or contaminated environments (C1). Human infection tends to result in (E1) mild clinical illness (E1). However, globally, there have been some (E2) hospitalized cases (E2) and (E2) two fatal cases (E2) reported in the past.",animal contact,illness severity
2024-DON523,contact with infected poultry or contaminated environments,hospitalized cases,T1,"Most human cases of infection with avian influenza A(H9N2) viruses are exposed to the virus through (C1) contact with infected poultry or contaminated environments (C1). Human infection tends to result in (E1) mild clinical illness (E1). However, globally, there have been some (E2) hospitalized cases (E2) and (E2) two fatal cases (E2) reported in the past.",animal contact,healthcare impact
2024-DON523,contact with infected poultry or contaminated environments,two fatal cases,T1,"Most human cases of infection with avian influenza A(H9N2) viruses are exposed to the virus through (C1) contact with infected poultry or contaminated environments (C1). Human infection tends to result in (E1) mild clinical illness (E1). However, globally, there have been some (E2) hospitalized cases (E2) and (E2) two fatal cases (E2) reported in the past.",animal contact,mortality rate
2024-DON523,continued detection of the virus in poultry populations,likelihood of human-to-human spread is low,T1,"Given the continued detection of the virus in poultry populations, (C1) sporadic human cases (C1) can be expected. No additional confirmed cases have been reported in the local area based on joint investigations. Currently, available epidemiological and virological evidence suggests that this virus has not acquired the ability to be sustained in transmission among humans. Thus, the (E1) likelihood of human-to-human spread (E1) is low.",animal reservoir,transmission likelihood
2024-DON523,ability to transmit easily among humans,community-level spread,T1,"However, the risk assessment will be reviewed should further epidemiological or virological information become available. International travellers from affected regions may present with infections either during their travels or after arrival in other countries. Even if this were to occur, further (E1) community-level spread (E1) is considered unlikely as this virus has not acquired the (C1) ability to transmit easily among humans (C1).",disease spread,population transmission
2024-DON521,population is likely highly susceptible,risk of additional case detection,T1,"This is the first detection of the disease in the country, therefore, the (C1) population is likely highly susceptible (C1) and there is a significant (E1) risk of additional case detection (E1). To date, there is no evidence of human-to-human Oropouche virus transmission. In the Region of the Americas, outbreaks of Oropouche virus disease have occurred mainly in the Amazon region over the past 10 years.",susceptibility factors,case detection
2024-DON521,Cuba is an international tourist destination and the putative vector is widely distributed in the Americas region,risk of the disease spreading internationally,T3,"The virus is endemic in many South American countries, in both rural and urban communities. Outbreaks are periodically reported in Brazil, Bolivia, Colombia, Ecuador, French Guiana, Panama, Peru, and Trinidad and Tobago. There is a (E1) risk of the disease spreading internationally (E1) as (C1) Cuba is an international tourist destination (C1) and the (C1) putative vector is widely distributed in the Americas region (C1). Additionally, there are currently other countries with (C2) active OROV circulation (C2).",travel exposure,global transmission
2024-DON521,active OROV circulation,risk of the disease spreading internationally,T3,"The virus is endemic in many South American countries, in both rural and urban communities. Outbreaks are periodically reported in Brazil, Bolivia, Colombia, Ecuador, French Guiana, Panama, Peru, and Trinidad and Tobago. There is a (E1) risk of the disease spreading internationally (E1) as (C1) Cuba is an international tourist destination (C1) and the (C1) putative vector is widely distributed in the Americas region (C1). Additionally, there are currently other countries with (C2) active OROV circulation (C2).",viral activity,global transmission
2024-DON519,exposure to infected poultry or contaminated environments,severe disease,T1,"This is the first human infection with an avian influenza A(H5N1) virus reported by Australia. Most human cases of infection with avian influenza viruses reported to date have been due to (C1) exposure to infected poultry or contaminated environments (C1). Currently, the likely source of exposure to the virus in the case remains unknown but likely occurred in India where the patient travelled before onset of illness. Human infection can cause (E1) severe disease (E1) and has a (E2) high mortality rate (E2).",animal exposure,disease severity
2024-DON519,exposure to infected poultry or contaminated environments,high mortality rate,T1,"This is the first human infection with an avian influenza A(H5N1) virus reported by Australia. Most human cases of infection with avian influenza viruses reported to date have been due to (C1) exposure to infected poultry or contaminated environments (C1). Currently, the likely source of exposure to the virus in the case remains unknown but likely occurred in India where the patient travelled before onset of illness. Human infection can cause (E1) severe disease (E1) and has a (E2) high mortality rate (E2).",animal exposure,disease severity
2024-DON519,"virus continues to circulate in poultry, particularly in rural areas",potential for further sporadic human cases,T1,"These A(H5N1) influenza viruses, belonging to different genetic groups, do not easily infect humans, and human-to-human transmission thus far appears unusual. As the (C1) virus continues to circulate in poultry, particularly in rural areas (C1), the (E1) potential for further sporadic human cases (E1) remains. Currently, available epidemiological and virological evidence suggests that A(H5) viruses have not acquired the ability of sustained transmission among humans, thus, the likelihood of human-to-human spread is low. Based on available information, WHO assesses the current risk to the general population posed by this virus as low. The risk assessment will be reviewed if additional virological and epidemiological information becomes available.",animal reservoir,disease occurrence
2024-DON520,avian influenza viruses are circulating in poultry,risk for infection and small clusters of human cases,T1,"This is the first laboratory-confirmed human case of infection with an influenza A(H5N2) virus reported globally, and the first A(H5) virus infection in a person reported in Mexico. The case had multiple underlying conditions, and the investigation by the health authorities in Mexico is ongoing to determine the likely source of exposure to the virus. Influenza A(H5N2) viruses have been detected in poultry in Mexico recently. Whenever (C1) avian influenza viruses are circulating in poultry (C1), there is a (E1) risk for infection and small clusters of human cases (E1) due to (C2) exposure to infected poultry or contaminated environments (C2).",animal diseases,disease clusters
2024-DON520,exposure to infected poultry or contaminated environments,risk for infection and small clusters of human cases,T1,"This is the first laboratory-confirmed human case of infection with an influenza A(H5N2) virus reported globally, and the first A(H5) virus infection in a person reported in Mexico. The case had multiple underlying conditions, and the investigation by the health authorities in Mexico is ongoing to determine the likely source of exposure to the virus. Influenza A(H5N2) viruses have been detected in poultry in Mexico recently. Whenever (C1) avian influenza viruses are circulating in poultry (C1), there is a (E1) risk for infection and small clusters of human cases (E1) due to (C2) exposure to infected poultry or contaminated environments (C2).",animal exposure,disease clusters
2024-DON520,A(H5) viruses from previous events have not acquired the ability to sustain transmission between humans,current likelihood of sustained human-to-human spread is low,T1,"Available epidemiological and virological evidence suggests that (C1) A(H5) viruses from previous events have not acquired the ability to sustain transmission between humans (C1), thus the (E1) current likelihood of sustained human-to-human spread is low (E1).",virus transmission,transmission risk
2024-DON520,no specific vaccines for preventing influenza A(H5) virus infection in humans,[No relevant effect related to disease transmission or emergence],[Not applicable],"According to the information available thus far, no further human cases of infection with A(H5N2) associated with this case have been detected. There are (C1) no specific vaccines for preventing influenza A(H5) virus infection in humans (C1). Candidate vaccines to prevent A(H5) infection in humans have been developed for pandemic preparedness purposes.",vaccine development,No impact
2024-DON520,,,No causality,"Close analysis of the epidemiological situation, further characterization of the most recent viruses (in human and birds) and serological investigations are critical to assess associated risks and to adjust risk management measures in a timely manner. Based on the available information, WHO assesses the current risk to the general population posed by this virus to be low. If needed, the risk assessment will be reviewed should further epidemiological or virological information, including information on A(H5N2) viruses detected in local animal populations, become available.",No context,No context
2024-DON518,DENV has the potential to cause epidemics,high morbidity and mortality,T1,"Dengue is a mosquito-borne viral disease caused by the dengue virus, with the potential to cause a serious public health impact. Dengue infections are the most common vector-borne viral infections worldwide, particularly impacting tropical and subtropical countries. (C1) DENV has the potential to cause epidemics (C1) resulting in (E1) high morbidity and mortality (E1). The virus is primarily transmitted through the (C2) bite of infected Aedes mosquitoes (C2), most commonly Aedes aegypti and Aedes albopictus.",disease outbreaks,health impact
2024-DON518,bite of infected Aedes mosquitoes,transmission of the virus,T1,"Dengue is a mosquito-borne viral disease caused by the dengue virus, with the potential to cause a serious public health impact. Dengue infections are the most common vector-borne viral infections worldwide, particularly impacting tropical and subtropical countries. (C1) DENV has the potential to cause epidemics (C1) resulting in (E1) high morbidity and mortality (E1). The virus is primarily transmitted through the (C2) bite of infected Aedes mosquitoes (C2), most commonly Aedes aegypti and Aedes albopictus.",vector transmission,disease transmission
2024-DON518,"climatic factors such as temperature, humidity and rainfall",new areas of local transmission,T1,"The proliferation and propagation of mosquitoes depend on (C1) climatic factors such as temperature, humidity and rainfall (C1). The arbovirus can be carried by (C2) infected travellers (imported cases) (C2) and may establish (E1) new areas of local transmission (E1) in the presence of (C3) vectors and a susceptible population (C3). As they are arboviruses, all populations living in areas with the presence of Aedes aegypti are at risk, however, their impact largely affects the (C4) most vulnerable people (C4), in which the arboviral disease programs do not have enough resources to respond to (E2) outbreaks (E2). Infection with one of the dengue serotypes (1-4) does not provide cross-protective immunity to the others, so persons living in a dengue endemic area can have (E3) four dengue infections during their lifetimes (E3).",environmental conditions,disease spread
2024-DON518,infected travellers (imported cases),new areas of local transmission,T3,"The proliferation and propagation of mosquitoes depend on (C1) climatic factors such as temperature, humidity and rainfall (C1). The arbovirus can be carried by (C2) infected travellers (imported cases) (C2) and may establish (E1) new areas of local transmission (E1) in the presence of (C3) vectors and a susceptible population (C3). As they are arboviruses, all populations living in areas with the presence of Aedes aegypti are at risk, however, their impact largely affects the (C4) most vulnerable people (C4), in which the arboviral disease programs do not have enough resources to respond to (E2) outbreaks (E2). Infection with one of the dengue serotypes (1-4) does not provide cross-protective immunity to the others, so persons living in a dengue endemic area can have (E3) four dengue infections during their lifetimes (E3).",travel transmission,disease spread
2024-DON518,vectors and a susceptible population,new areas of local transmission,T3,"The proliferation and propagation of mosquitoes depend on (C1) climatic factors such as temperature, humidity and rainfall (C1). The arbovirus can be carried by (C2) infected travellers (imported cases) (C2) and may establish (E1) new areas of local transmission (E1) in the presence of (C3) vectors and a susceptible population (C3). As they are arboviruses, all populations living in areas with the presence of Aedes aegypti are at risk, however, their impact largely affects the (C4) most vulnerable people (C4), in which the arboviral disease programs do not have enough resources to respond to (E2) outbreaks (E2). Infection with one of the dengue serotypes (1-4) does not provide cross-protective immunity to the others, so persons living in a dengue endemic area can have (E3) four dengue infections during their lifetimes (E3).",disease spread,disease spread
2024-DON518,most vulnerable people,outbreaks,T1,"The proliferation and propagation of mosquitoes depend on (C1) climatic factors such as temperature, humidity and rainfall (C1). The arbovirus can be carried by (C2) infected travellers (imported cases) (C2) and may establish (E1) new areas of local transmission (E1) in the presence of (C3) vectors and a susceptible population (C3). As they are arboviruses, all populations living in areas with the presence of Aedes aegypti are at risk, however, their impact largely affects the (C4) most vulnerable people (C4), in which the arboviral disease programs do not have enough resources to respond to (E2) outbreaks (E2). Infection with one of the dengue serotypes (1-4) does not provide cross-protective immunity to the others, so persons living in a dengue endemic area can have (E3) four dengue infections during their lifetimes (E3).",population vulnerability,disease spread
2024-DON518,Changes in the predominant circulating serotype,increase the population risk of subsequent exposure to a heterologous DENV serotype,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",serotype variation,disease exposure
2024-DON518,increase the population risk of subsequent exposure to a heterologous DENV serotype,increases the risk of higher rates of severe dengue and deaths,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",disease exposure,disease severity
2024-DON518,Changing distribution of the Aedes aegypti vector,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",vector distribution,disease spread
2024-DON518,Urbanization and human activities fostering conducive environments for vector-host interaction,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",urban development,epidemic risk
2024-DON518,Climate change-induced shifts in weather patterns,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",environmental factors,epidemic risk
2024-DON518,Fragile healthcare systems amidst political and financial instabilities,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",systemic vulnerability,epidemic risk
2024-DON518,Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",serotype variation,epidemic risk
2024-DON518,Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",diagnostic challenges,epidemic expansion
2024-DON518,Inadequate laboratory and testing capacity,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",testing limitations,epidemic risk
2024-DON518,"Prolonged ongoing concurrent outbreaks, including COVID-19",increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",disease outbreaks,epidemic risk
2024-DON518,"Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management",increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",systemic unpreparedness,epidemic risk
2024-DON518,Lack of specific treatment for dengue,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",treatment deficiency,disease spread
2024-DON518,Lack of engagement and mobilization of local communities in vector control activities,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",community involvement,epidemic risk
2024-DON518,Insufficient vector surveillance and control capacities,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",vector control,epidemic risk
2024-DON518,"Lack of coordination among stakeholders, chronic underfunding, and low donor interest",increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",funding challenges,epidemic risk
2024-DON518,Lack of involvement of government sectors responsible for addressing social determinants,increasing risk of dengue epidemics becoming more extensive and less predictable,T1,"Changes in the predominant circulating serotype (C1) increase the population risk of subsequent exposure to a heterologous DENV serotype (E1, C2), which increases the risk of higher rates of severe dengue and deaths (E2). Severe dengue is characterized by vascular leakage, hemorrhagic manifestations, thrombocytopenia, and hypotensive shock, which can lead to organ failure and death. Age, interval between infections, antibody characteristics, viral factors, and host-specific genetics are contributing factors. Monitoring of the global dengue situation to date has shown that several factors are associated with an increasing risk of dengue epidemics becoming more extensive and less predictable, and these include: Changing distribution of the Aedes aegypti vector (C3); Urbanization and human activities fostering conducive environments for vector-host interaction (C4); Climate change-induced shifts in weather patterns (C5); Fragile healthcare systems amidst political and financial instabilities (C6); Changes in the predominant circulating serotypes and co-circulation of multiple dengue serotypes (C7); Challenges in clinical diagnosis particularly in areas with co-circulation of other arboviruses (C8); Inadequate laboratory and testing capacity (C9); Prolonged ongoing concurrent outbreaks, including COVID-19 (C10); Insufficient preparedness for the scale of the epidemic, and low capacity for dengue patient clinical management (C11); Lack of specific treatment for dengue (C12); Lack of engagement and mobilization of local communities in vector control activities (C13); Insufficient vector surveillance and control capacities (C14); Lack of coordination among stakeholders, chronic underfunding, and low donor interest (C15); Lack of involvement of government sectors responsible for addressing social determinants (C16).",policy neglect,epidemic expansion
2024-DON518,Lack of engagement and mobilization of local communities in vector control activities,implementation of policies aimed at improving conditions related to the risk of transmission,T1,"The (E1) implementation of policies aimed at improving conditions related to the risk of transmission (E1), such as urban planning, water and sanitation provision, solid waste management, housing improvement, etc. (C1) Lack of engagement and mobilization of local communities in vector control activities (C1). WHO assessed the global risk of dengue as high on 30 November 2023, and subsequently assigned a WHO internal emergency response grade of G3 at the global level on 1 December 2023. Given the current scale of the dengue outbreaks, the potential risk of further international spread and the complexity of factors impacting transmission, the overall risk at the global level is still assessed as high and thus dengue remains a global threat to public health.",community involvement,policy implementation
2024-DON516,dromedaries,MERS-CoV infection,T1,"The notification of these cases does not change the overall risk assessment. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where MERS-CoV is circulating in (C1) dromedaries (C1). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, (C2) consumption of raw camel milk (C2)), or in a (C3) health-care setting (C3).",animal reservoir,disease transmission
2024-DON516,contact with dromedaries or their products,cases exported to other countries,T1,"The notification of these cases does not change the overall risk assessment. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where MERS-CoV is circulating in (C1) dromedaries (C1). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, (C2) consumption of raw camel milk (C2)), or in a (C3) health-care setting (C3).",animal contact,global spread
2024-DON516,consumption of raw camel milk,cases exported to other countries,T1,"The notification of these cases does not change the overall risk assessment. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where MERS-CoV is circulating in (C1) dromedaries (C1). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, (C2) consumption of raw camel milk (C2)), or in a (C3) health-care setting (C3).",food consumption,global spread
2024-DON516,health-care setting,cases exported to other countries,T1,"The notification of these cases does not change the overall risk assessment. WHO expects that additional cases of MERS-CoV infection will be reported from the Middle East and/or other countries where MERS-CoV is circulating in (C1) dromedaries (C1). In addition, cases will continue to be exported to other countries by individuals who were exposed to the virus through (C2) contact with dromedaries or their products (C2) (for example, (C2) consumption of raw camel milk (C2)), or in a (C3) health-care setting (C3).",medical environment,global spread
2024-DON516,,,No causality,WHO continues to monitor the epidemiological situation and conducts risk assessments based on the latest available information.,No context,No context
2024-DON517,influx of refugees and returnees fleeing armed conflict,risk at the national level,T1,"The outbreak is occurring in the Ouaddai province which has been heavily affected by an (C1) influx of refugees and returnees fleeing armed conflict in neighbouring Sudan since April 2023 (C1). The majority of hepatitis E cases have been reported from the Adr&eacute; health district hosting three refugee camps with an average of 50&nbsp;000 refugees per camp and a temporary refugee site housing approximately 170&nbsp;000 refugees (UNHCR estimate). The (E1) risk at the national level (E1) is assessed as high due to the (C2) continuous population movements between different refugee camps and host communities (C2); (C3) poor hygiene conditions (C3), (C3) low access to safe drinking water and improved sanitation facilities including wastewater management (C3) as well as (C3) limited access to essential medical services in the affected camps (C3); (C4) challenges in the management of cases among pregnant women (C4). In addition, the (C5) limited financial capacity to effectively contain the outbreak (C5) also contributes to increasing the (E2) risk of spreading the disease in the Ouaddai province and across the rest of the country (E2). Although no ongoing outbreak of hepatitis E has been reported officially in countries bordering Chad, the overall (E3) risk at the regional level (E3) is considered moderate because of the (C6) continued population movements between Chad and Sudan or the Central African Republic (C6) that raise fears of the spread of the epidemic in the sub-region.",population movement,policy evaluation
2024-DON517,continuous population movements between different refugee camps and host communities,risk at the national level,T3,"The outbreak is occurring in the Ouaddai province which has been heavily affected by an (C1) influx of refugees and returnees fleeing armed conflict in neighbouring Sudan since April 2023 (C1). The majority of hepatitis E cases have been reported from the Adr&eacute; health district hosting three refugee camps with an average of 50&nbsp;000 refugees per camp and a temporary refugee site housing approximately 170&nbsp;000 refugees (UNHCR estimate). The (E1) risk at the national level (E1) is assessed as high due to the (C2) continuous population movements between different refugee camps and host communities (C2); (C3) poor hygiene conditions (C3), (C3) low access to safe drinking water and improved sanitation facilities including wastewater management (C3) as well as (C3) limited access to essential medical services in the affected camps (C3); (C4) challenges in the management of cases among pregnant women (C4). In addition, the (C5) limited financial capacity to effectively contain the outbreak (C5) also contributes to increasing the (E2) risk of spreading the disease in the Ouaddai province and across the rest of the country (E2). Although no ongoing outbreak of hepatitis E has been reported officially in countries bordering Chad, the overall (E3) risk at the regional level (E3) is considered moderate because of the (C6) continued population movements between Chad and Sudan or the Central African Republic (C6) that raise fears of the spread of the epidemic in the sub-region.",population movement,policy evaluation
2024-DON517,"poor hygiene conditions, low access to safe drinking water and improved sanitation facilities, limited access to essential medical services",risk at the national level,T3,"The outbreak is occurring in the Ouaddai province which has been heavily affected by an (C1) influx of refugees and returnees fleeing armed conflict in neighbouring Sudan since April 2023 (C1). The majority of hepatitis E cases have been reported from the Adr&eacute; health district hosting three refugee camps with an average of 50&nbsp;000 refugees per camp and a temporary refugee site housing approximately 170&nbsp;000 refugees (UNHCR estimate). The (E1) risk at the national level (E1) is assessed as high due to the (C2) continuous population movements between different refugee camps and host communities (C2); (C3) poor hygiene conditions (C3), (C3) low access to safe drinking water and improved sanitation facilities including wastewater management (C3) as well as (C3) limited access to essential medical services in the affected camps (C3); (C4) challenges in the management of cases among pregnant women (C4). In addition, the (C5) limited financial capacity to effectively contain the outbreak (C5) also contributes to increasing the (E2) risk of spreading the disease in the Ouaddai province and across the rest of the country (E2). Although no ongoing outbreak of hepatitis E has been reported officially in countries bordering Chad, the overall (E3) risk at the regional level (E3) is considered moderate because of the (C6) continued population movements between Chad and Sudan or the Central African Republic (C6) that raise fears of the spread of the epidemic in the sub-region.",hygiene access,policy evaluation
2024-DON517,challenges in the management of cases among pregnant women,risk at the national level,T1,"The outbreak is occurring in the Ouaddai province which has been heavily affected by an (C1) influx of refugees and returnees fleeing armed conflict in neighbouring Sudan since April 2023 (C1). The majority of hepatitis E cases have been reported from the Adr&eacute; health district hosting three refugee camps with an average of 50&nbsp;000 refugees per camp and a temporary refugee site housing approximately 170&nbsp;000 refugees (UNHCR estimate). The (E1) risk at the national level (E1) is assessed as high due to the (C2) continuous population movements between different refugee camps and host communities (C2); (C3) poor hygiene conditions (C3), (C3) low access to safe drinking water and improved sanitation facilities including wastewater management (C3) as well as (C3) limited access to essential medical services in the affected camps (C3); (C4) challenges in the management of cases among pregnant women (C4). In addition, the (C5) limited financial capacity to effectively contain the outbreak (C5) also contributes to increasing the (E2) risk of spreading the disease in the Ouaddai province and across the rest of the country (E2). Although no ongoing outbreak of hepatitis E has been reported officially in countries bordering Chad, the overall (E3) risk at the regional level (E3) is considered moderate because of the (C6) continued population movements between Chad and Sudan or the Central African Republic (C6) that raise fears of the spread of the epidemic in the sub-region.",maternal health,policy evaluation
2024-DON517,limited financial capacity to effectively contain the outbreak,risk of spreading the disease in the Ouaddai province and across the rest of the country,T1,"The outbreak is occurring in the Ouaddai province which has been heavily affected by an (C1) influx of refugees and returnees fleeing armed conflict in neighbouring Sudan since April 2023 (C1). The majority of hepatitis E cases have been reported from the Adr&eacute; health district hosting three refugee camps with an average of 50&nbsp;000 refugees per camp and a temporary refugee site housing approximately 170&nbsp;000 refugees (UNHCR estimate). The (E1) risk at the national level (E1) is assessed as high due to the (C2) continuous population movements between different refugee camps and host communities (C2); (C3) poor hygiene conditions (C3), (C3) low access to safe drinking water and improved sanitation facilities including wastewater management (C3) as well as (C3) limited access to essential medical services in the affected camps (C3); (C4) challenges in the management of cases among pregnant women (C4). In addition, the (C5) limited financial capacity to effectively contain the outbreak (C5) also contributes to increasing the (E2) risk of spreading the disease in the Ouaddai province and across the rest of the country (E2). Although no ongoing outbreak of hepatitis E has been reported officially in countries bordering Chad, the overall (E3) risk at the regional level (E3) is considered moderate because of the (C6) continued population movements between Chad and Sudan or the Central African Republic (C6) that raise fears of the spread of the epidemic in the sub-region.",economic constraints,disease spread
2024-DON517,continued population movements between Chad and Sudan or the Central African Republic,risk at the regional level,T1,"The outbreak is occurring in the Ouaddai province which has been heavily affected by an (C1) influx of refugees and returnees fleeing armed conflict in neighbouring Sudan since April 2023 (C1). The majority of hepatitis E cases have been reported from the Adr&eacute; health district hosting three refugee camps with an average of 50&nbsp;000 refugees per camp and a temporary refugee site housing approximately 170&nbsp;000 refugees (UNHCR estimate). The (E1) risk at the national level (E1) is assessed as high due to the (C2) continuous population movements between different refugee camps and host communities (C2); (C3) poor hygiene conditions (C3), (C3) low access to safe drinking water and improved sanitation facilities including wastewater management (C3) as well as (C3) limited access to essential medical services in the affected camps (C3); (C4) challenges in the management of cases among pregnant women (C4). In addition, the (C5) limited financial capacity to effectively contain the outbreak (C5) also contributes to increasing the (E2) risk of spreading the disease in the Ouaddai province and across the rest of the country (E2). Although no ongoing outbreak of hepatitis E has been reported officially in countries bordering Chad, the overall (E3) risk at the regional level (E3) is considered moderate because of the (C6) continued population movements between Chad and Sudan or the Central African Republic (C6) that raise fears of the spread of the epidemic in the sub-region.",population movement,geographic risk
2024-DON517,,,No causality,"At the global level, the risk is considered low.",No context,No context
2024-DON514,contact with infected poultry or contaminated environments,mild clinical illness,T1,Most human cases of infection with avian influenza A(H9N2) viruses are exposed to the virus through (C1) contact with infected poultry or contaminated environments (C1). Human infection tends to result in (E1) mild clinical illness (E1). Further human cases can be expected since the (C2) virus continues to be detected in poultry populations (C2).,animal contact,illness severity
2024-DON514,virus continues to be detected in poultry populations,further human cases can be expected,T1,Most human cases of infection with avian influenza A(H9N2) viruses are exposed to the virus through (C1) contact with infected poultry or contaminated environments (C1). Human infection tends to result in (E1) mild clinical illness (E1). Further human cases can be expected since the (C2) virus continues to be detected in poultry populations (C2).,animal infection,disease expectation
2024-DON514,infection,likelihood of human-to-human spread,T1,"No clusters of cases have been reported. Currently available epidemiological and virological evidence suggests that this virus has not acquired the ability to be sustained in transmission among humans. Thus, the (E1) likelihood of human-to-human spread (E1) is low. Should infected individuals from affected areas travel internationally, their (C1) infection (C1) may be detected in another country during travel or after arrival.",disease transmission,disease spread
2024-DON514,ability to transmit easily among humans,community-level spread,T1,"If this were to occur, further (E1) community-level spread (E1) is considered unlikely as this virus has not acquired the (C1) ability to transmit easily among humans (C1).",disease spread,population transmission
2024-DON513,experience and awareness of community and health care workers on rabies are likely limited,risk at the national level is assessed as ‘High’,T3,"The (E1) risk at the national level (E1) is assessed as ‘High’ due to the following: The country was previously classified as “rabies free” and has now reported the first confirmed human case. As such, (C1) experience and awareness of community and health care workers on rabies are likely limited (C1). Oecusse, the municipality where the current case was bitten and reported from, is an enclave of Timor-Leste located within East Nusa Tenggara province (NTT) in Indonesia where (C2) rabies is endemic in both dogs and humans (C2), and where between 1 January and 15 March 2024, six human rabies deaths have been recorded. (C3) Insufficient stock of human rabies vaccines (C3) in the government health facilities. The health workers in the areas considered at high risk of rabies have been trained for dog-bite management. A recent survey shows that 91% of health workforce in Oecusse have demonstrated knowledge of dog-bite management including PEP and RIG administration.",knowledge gaps,risk assessment
2024-DON513,rabies is endemic in both dogs and humans,risk at the national level is assessed as ‘High’,T3,"The (E1) risk at the national level (E1) is assessed as ‘High’ due to the following: The country was previously classified as “rabies free” and has now reported the first confirmed human case. As such, (C1) experience and awareness of community and health care workers on rabies are likely limited (C1). Oecusse, the municipality where the current case was bitten and reported from, is an enclave of Timor-Leste located within East Nusa Tenggara province (NTT) in Indonesia where (C2) rabies is endemic in both dogs and humans (C2), and where between 1 January and 15 March 2024, six human rabies deaths have been recorded. (C3) Insufficient stock of human rabies vaccines (C3) in the government health facilities. The health workers in the areas considered at high risk of rabies have been trained for dog-bite management. A recent survey shows that 91% of health workforce in Oecusse have demonstrated knowledge of dog-bite management including PEP and RIG administration.",disease prevalence,risk assessment
2024-DON513,Insufficient stock of human rabies vaccines,risk at the national level is assessed as ‘High’,T3,"The (E1) risk at the national level (E1) is assessed as ‘High’ due to the following: The country was previously classified as “rabies free” and has now reported the first confirmed human case. As such, (C1) experience and awareness of community and health care workers on rabies are likely limited (C1). Oecusse, the municipality where the current case was bitten and reported from, is an enclave of Timor-Leste located within East Nusa Tenggara province (NTT) in Indonesia where (C2) rabies is endemic in both dogs and humans (C2), and where between 1 January and 15 March 2024, six human rabies deaths have been recorded. (C3) Insufficient stock of human rabies vaccines (C3) in the government health facilities. The health workers in the areas considered at high risk of rabies have been trained for dog-bite management. A recent survey shows that 91% of health workforce in Oecusse have demonstrated knowledge of dog-bite management including PEP and RIG administration.",vaccine shortage,risk assessment
2024-DON513,health workers have limited knowledge dog bite and scratch case management including PEP and RIG administration,[No explicit effect mentioned],[T1] (Note: The effect is implied but not explicitly stated in the text),"However, in other parts of Timor-Leste (C1) health workers have limited knowledge dog bite and scratch case management including PEP and RIG administration (C1). The rabies case management guidelines have yet to be finalized and training needs to be conducted on clinical management. Timor-Leste has a significant population owning dogs and more than 70% vaccinated in the areas bordering Indonesia. Dog vaccination programme is continuing very effectively.",healthcare training,non-specific effect
2024-DON513,limited human resources,risk of the international spread of rabies from Timor-Leste to other countries is unlikely,T1,"Currently more than 35,000 dogs are vaccinated as of 24 April 2024. Despite (C1) limited human resources (C1), 102 dog vaccinators are doing door-to-door campaigns in the border areas and Dili to provide dog vaccine. The frontliners from human health and those considered at higher risk have not received pre-exposure vaccine due to (C2) non-availability of the same (C2). Since Timor-Leste's only land border is with NTT province in Indonesia, which is already endemic for rabies (humans and canines), the (E1) risk of the international spread of rabies from Timor-Leste to other countries (E1) is unlikely.",resource scarcity,disease spread
2024-DON513,non-availability of pre-exposure vaccine,risk of the international spread of rabies from Timor-Leste to other countries is unlikely,T1,"Currently more than 35,000 dogs are vaccinated as of 24 April 2024. Despite (C1) limited human resources (C1), 102 dog vaccinators are doing door-to-door campaigns in the border areas and Dili to provide dog vaccine. The frontliners from human health and those considered at higher risk have not received pre-exposure vaccine due to (C2) non-availability of the same (C2). Since Timor-Leste's only land border is with NTT province in Indonesia, which is already endemic for rabies (humans and canines), the (E1) risk of the international spread of rabies from Timor-Leste to other countries (E1) is unlikely.",vaccine access,disease spread
2024-DON513,,,No causality,"Available data indicates only the current one fatal case of rabies in Timor-Leste, with no links to international travel, tourism or international gatherings.",No context,No context
2024-DON512,avian influenza viruses are circulating in birds,risk for sporadic infections in mammals and humans,T1,"This human case was reportedly exposed to dairy cattle in Texas, where HPAI A (H5N1) has recently been confirmed in dairy herds. From 2003 to 1 April 2024, a total of 889 cases and 463 deaths (CFR 52%) caused by influenza A(H5N1) virus have been reported worldwide from 23 countries. The most recently reported case in humans prior to the current case, was in March 2024 in Viet Nam. The human case in Texas is the fourth reported in the region of the Americas, the most recent prior case having been reported in Chile in March 2023. Whenever (C1) avian influenza viruses are circulating in birds (C1), there is a (E1) risk for sporadic infections in mammals and humans (E1) due to (C2) exposure to infected animals (including livestock) (C2), or (C2) contaminated environments (C2) and thus, further human cases are not unexpected. Influenza A infection has been rarely reported in bovine species and spread among dairy cattle herds in four U.S. States is being assessed.",animal transmission,infection risk
2024-DON512,"exposure to infected animals (including livestock), or contaminated environments",risk for sporadic infections in mammals and humans,T3,"This human case was reportedly exposed to dairy cattle in Texas, where HPAI A (H5N1) has recently been confirmed in dairy herds. From 2003 to 1 April 2024, a total of 889 cases and 463 deaths (CFR 52%) caused by influenza A(H5N1) virus have been reported worldwide from 23 countries. The most recently reported case in humans prior to the current case, was in March 2024 in Viet Nam. The human case in Texas is the fourth reported in the region of the Americas, the most recent prior case having been reported in Chile in March 2023. Whenever (C1) avian influenza viruses are circulating in birds (C1), there is a (E1) risk for sporadic infections in mammals and humans (E1) due to (C2) exposure to infected animals (including livestock) (C2), or (C2) contaminated environments (C2) and thus, further human cases are not unexpected. Influenza A infection has been rarely reported in bovine species and spread among dairy cattle herds in four U.S. States is being assessed.",animal exposure,infection risk
2024-DON512,no specific vaccines for preventing influenza A(H5N1) virus infection in humans,transmission among humans,T1,"Previously, there have been human infections with other avian influenza subtypes following exposure to infected mammals. Since the virus has not acquired mutations that facilitate (E1) transmission among humans (E1) and based on available information, WHO assesses the public health risk to the general population posed by this virus to be low and for occupationally exposed persons the risk of infection is considered low-to-moderate. There are (C1) no specific vaccines for preventing influenza A(H5N1) virus infection in humans (C1). Candidate vaccines to prevent H5 infection in humans have been developed for pandemic preparedness purposes.",vaccine development,human transmission
2024-DON512,,,No causality,"Close analysis of the epidemiological situation, further characterization of the most recent viruses (from human cases and animal) and comprehensive investigations around human cases are critical to assess associated risk and to adjust risk management measures in a timely manner. If needed, the risk assessment will be reviewed should further epidemiological or virological information become available.",No context,No context
2024-DON511,exposure to infected poultry or contaminated environments,severe disease,T1,"This is the first human infection with an avian influenza A (H5N1) virus reported in Viet Nam in 2024, and since 2022. Most human cases of infection with avian influenza viruses reported to date have been due to (C1) exposure to infected poultry or contaminated environments (C1). Human infection can cause (E1) severe disease (E1) and has a (E2) high mortality rate (E2). These A(H5N1) influenza viruses, belonging to different genetic groups, do not easily infect humans, and human-to-human transmission thus far appears unusual.",animal exposure,disease severity
2024-DON511,exposure to infected poultry or contaminated environments,high mortality rate,T1,"This is the first human infection with an avian influenza A (H5N1) virus reported in Viet Nam in 2024, and since 2022. Most human cases of infection with avian influenza viruses reported to date have been due to (C1) exposure to infected poultry or contaminated environments (C1). Human infection can cause (E1) severe disease (E1) and has a (E2) high mortality rate (E2). These A(H5N1) influenza viruses, belonging to different genetic groups, do not easily infect humans, and human-to-human transmission thus far appears unusual.",animal exposure,disease severity
2024-DON511,"virus continues to circulate in poultry, particularly in rural areas of Viet Nam",potential for further sporadic human cases,T1,"As the (C1) virus continues to circulate in poultry, particularly in rural areas of Viet Nam (C1), the (E1) potential for further sporadic human cases (E1) remains. Currently, available epidemiological and virological evidence suggests that A(H5) viruses have not acquired the ability of sustained transmission among humans; thus, the likelihood of human-to-human spread is low. Based on available information, WHO assesses the risk to the general population posed by this virus as low. The risk assessment will be reviewed if additional virological and epidemiological information becomes available.",animal transmission,disease occurrence
2024-DON510,persisting immunity gaps,resurgence of YF outbreaks,T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",immunity deficiency,disease resurgence
2024-DON510,persistence of pockets of unimmunized populations,resurgence of YF outbreaks,T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",vaccine coverage,disease resurgence
2024-DON510,high population density and international travel connections,significant risks of YF spread,T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",global mobility,disease spread
2024-DON510,risk of cross-border spread,significant risks of YF spread,T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",disease spread,disease spread
2024-DON510,limited surveillance and laboratory capacity,"delayed detection, underestimation of the extent of the disease and delayed response",T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",healthcare infrastructure,detection delay
2024-DON510,competing health emergencies,persisting response challenges,T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",health challenges,response challenges
2024-DON510,competing outbreaks,strain the capacity to respond effectively,T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",disease competition,response capacity
2024-DON510,"food insecurity, security constraints, and complex humanitarian contexts",compounded challenges in response,T1,"As part of the ongoing efforts to monitor and respond to infectious disease outbreaks, on 12 February 2024, the World Health Organization conducted a Rapid Risk Assessment for yellow fever. It aimed to reassess the current regional risk of multiple ongoing YF outbreaks, in the context of a resurgence of YF outbreaks in countries with a history of preventive vaccination campaigns and (C1) persisting immunity gaps (C1), including capacities to support the response (e.g., technical capacities, vaccine supply and vaccination campaigns, laboratory and operations, support and logistics (OSL)) and to provide recommendations for a more effective and coordinated response. The overall risk at the regional level was re-assessed as moderate based on several contributing factors observed in the region despite the efforts to control the spread of YF: Stable number of ongoing outbreaks across the region. (C2) Persistence of pockets of unimmunized populations (C2) although considerable efforts have been made in recent years to protect the population through PMVC and reactive mass vaccination campaigns (RMVC). Detection of YF confirmed cases in urban areas, such as Douala city in Cameroon, which pose significant risks due to (C3) high population density (C3) and (C3) international travel connections (C3), noting nevertheless the risk mitigation provided by a relatively high average vaccination coverage. (C4) Risk of cross-border spread (C4), particularly from the outbreak in South Sudan, which shares borders with neighbouring countries. (C5) Limited surveillance and laboratory capacity (C5) in certain regions may result in (E1) delayed detection, underestimation of the extent of the disease and delayed response (E1). Persisting response challenges with the case classification, investigation, and response operations, exacerbated by (C6) competing health emergencies (C6). (C7) Competing outbreaks (C7) strain the capacity to respond effectively, with various simultaneous health crises, including measles, poliomyelitis, mpox, cholera, diphtheria, hepatitis E, Lassa fever, and dengue. These challenges are compounded by factors such as (C8) food insecurity (C8), (C8) security constraints (C8), and (C8) complex humanitarian contexts (C8).",crisis factors,response challenges
2024-DON510,"public health and medical personnel are overburdened, managing multiple parallel outbreaks alongside other health emergencies",challenge of controlling outbreaks effectively,T1,"Furthermore, (C1) public health and medical personnel are overburdened, managing multiple parallel outbreaks alongside other health emergencies (C1). (C2) Socio-economic factors, high levels of poverty and limited resource allocation (C2) contribute to the (E1) challenge of controlling outbreaks effectively (E1). While the global risk remains low, active surveillance is required due to the potential for onward transmission through (C3) viremic travellers (C3) and the (C3) presence of the competent vector in neighbouring regions (C3). While progress has been made in controlling outbreaks, ongoing challenges and vulnerabilities underscore the need for sustained and coordinated efforts to protect public health. The (E2) impact on public health (E2) will persist until the ongoing outbreaks are controlled, vaccination coverage is high and immunity gaps in the population closed. The (C4) importation of cases to countries with suboptimal coverage and persisting population immunity gaps (C4) poses a (E3) high risk (E3) and may jeopardize the tremendous efforts invested to achieve elimination.",healthcare strain,outbreak management
2024-DON510,"Socio-economic factors, high levels of poverty and limited resource allocation",challenge of controlling outbreaks effectively,T3,"Furthermore, (C1) public health and medical personnel are overburdened, managing multiple parallel outbreaks alongside other health emergencies (C1). (C2) Socio-economic factors, high levels of poverty and limited resource allocation (C2) contribute to the (E1) challenge of controlling outbreaks effectively (E1). While the global risk remains low, active surveillance is required due to the potential for onward transmission through (C3) viremic travellers (C3) and the (C3) presence of the competent vector in neighbouring regions (C3). While progress has been made in controlling outbreaks, ongoing challenges and vulnerabilities underscore the need for sustained and coordinated efforts to protect public health. The (E2) impact on public health (E2) will persist until the ongoing outbreaks are controlled, vaccination coverage is high and immunity gaps in the population closed. The (C4) importation of cases to countries with suboptimal coverage and persisting population immunity gaps (C4) poses a (E3) high risk (E3) and may jeopardize the tremendous efforts invested to achieve elimination.",social determinants,outbreak management
2024-DON510,viremic travellers and the presence of the competent vector in neighbouring regions,impact on public health,T3,"Furthermore, (C1) public health and medical personnel are overburdened, managing multiple parallel outbreaks alongside other health emergencies (C1). (C2) Socio-economic factors, high levels of poverty and limited resource allocation (C2) contribute to the (E1) challenge of controlling outbreaks effectively (E1). While the global risk remains low, active surveillance is required due to the potential for onward transmission through (C3) viremic travellers (C3) and the (C3) presence of the competent vector in neighbouring regions (C3). While progress has been made in controlling outbreaks, ongoing challenges and vulnerabilities underscore the need for sustained and coordinated efforts to protect public health. The (E2) impact on public health (E2) will persist until the ongoing outbreaks are controlled, vaccination coverage is high and immunity gaps in the population closed. The (C4) importation of cases to countries with suboptimal coverage and persisting population immunity gaps (C4) poses a (E3) high risk (E3) and may jeopardize the tremendous efforts invested to achieve elimination.",travel transmission,health impact
2024-DON510,importation of cases to countries with suboptimal coverage and persisting population immunity gaps,high risk,T1,"Furthermore, (C1) public health and medical personnel are overburdened, managing multiple parallel outbreaks alongside other health emergencies (C1). (C2) Socio-economic factors, high levels of poverty and limited resource allocation (C2) contribute to the (E1) challenge of controlling outbreaks effectively (E1). While the global risk remains low, active surveillance is required due to the potential for onward transmission through (C3) viremic travellers (C3) and the (C3) presence of the competent vector in neighbouring regions (C3). While progress has been made in controlling outbreaks, ongoing challenges and vulnerabilities underscore the need for sustained and coordinated efforts to protect public health. The (E2) impact on public health (E2) will persist until the ongoing outbreaks are controlled, vaccination coverage is high and immunity gaps in the population closed. The (C4) importation of cases to countries with suboptimal coverage and persisting population immunity gaps (C4) poses a (E3) high risk (E3) and may jeopardize the tremendous efforts invested to achieve elimination.",global spread,risk factors
